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1. ABSTRACT 
Glycogen synthase kinase 3 (GSK3) plays a decisive role in the regulation of multiple 
functions and acts as  a downstream regulatory switch for various signaling pathways, 
including cellular responses to WNT, Growth Factors, Insulin, RTK (Receptor Tyrosine 
Kinases), Hedgehog pathways, and GPCR (G-Protein-Coupled Receptors) and is involved in 
a numerous signal transduction cascades involving cellular processes, ranging from glycogen 
metabolism, cell development, gene transcription, protein translation to cytoskeletal 
organization, cell cycle regulation, proliferation and apoptosis.  
GSK3 is phosphorylated and its activity is inhibited by protein kinase B (PKB/Akt) and serum 
& glucocorticoid inducible kinase (SGK) isoforms, which are in turn activated by growth factors 
through phosphoinositide (PI) 3 kinase signalling.  
In addition, abnormally high activities of GSK-3 protein (overexpression) have been 
implicated in several pathological disorders which include type 2 diabetes, neuron 
degenerative and affective disorders. This led to the development of new generations of 
inhibitors with specific clinical implications to treat these diseases. 
PI3/PKB/Akt/SGK-dependent inhibition of GSK3 is disrupted in gene targeted knockin mice 
with mutated and thus PKB/SGK-resistant GSK3α,ß (gsk3KI) where the serine of the PKB/SGK 
phosphorylation site has been replaced by alanine.  Thus our GSK3KI
Recent experiments revealed that blood pressure is significantly higher in these mice 
(gsk3
 mouse is with 
overexpressed GSK3 activity which in turns resistant to PI3/PKB/Akt/SGK signalling pathway. 
KI) than in wild type mice (gsk3WT
Looking forward to the first aim, we determined blood pressure with the tail cuff 
method, heart rate by ECG-measurements, catecholamine concentrations by ELISA, and 
).  So to find out the underlying cause of elevated blood 
pressure was our first aim of this study.  As discussed earlier that Insulin and IGF1-dependent 
signaling activates protein kinase B and serum-glucocorticoid kinase (PKB/SGK), which 
together phosphorylate and inactivate glycogen synthase kinase GSK3.  Since insulin and 
IGF1 increase renal tubular calcium and phosphorus reabsorption and GSK3 plays important 
role in intestinal electrogenic phosphate transport. Our second aim of the study was to 
determine whether overexpression of GSK3 and the phosphate transporter NaPi-IIa in 
Xenopus oocytes decrease electrogenic phosphate transport and decrease renal tubular 
calcium and phosphorus reabsorption.  
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vanilylmandelic acid by HPLC. As a result, blood pressure and heart rate were significantly 
higher in gsk3KI than in gsk3WTmice. The α-adrenergic blocker prazosine (1 µg/g b.w.) and the 
ganglion blocker hexamethonium (40 µg/g b.w.) decreased blood pressure to a larger extent in 
gsk3KI than in gsk3WTmice and virtually abrogated the difference between genotypes. Similarly, 
the β-adrenergic blocker atenolol (5 µg/g b.w.) decreased the heart rate to a larger extent in 
gsk3KI than in gsk3WTmice and again dissipated the difference of heart rate between genotypes. 
Plasma epinephrine and norepinephrine concentrations, as well as urinary excretion of 
vanilylmandelic acid were significantly higher in gsk3KI than in gsk3WT
Looking forward to second aim, to determine creatinine clearance, urinary flow rate, 
and urinary excretion of Ca
mice. Thus, the 
observations reveal a completely novel function of PKB/Akt/SGK-dependent GSK3 signaling, 
i.e. regulation of catecholamine release.  
2+and phosphate, the mice were placed individually in metabolic 
cages for 24- our urine collection. The phosphate concentration was determined 
colorimetrically using commercial diagnostic kits. The urinary concentration of Ca2+ was 
measured by flame photometry or by a photometric method according to the manufacturer’s 
instructions. The creatinine concentration in urine was determined using the Jaffe reaction, 
creatinine and calcium concentration in plasma were measured using a photometric method. 
The plasma intact parathormone concentration was measured using an ELISA kit. A 
radioimmunassay kit was used to determine the concentration of 1,25-(OH)2D3 in plasma. 
The bone density was determined by high-resolution microCAT-II small animal computed 
tomography (CT) scanner. Compared with wildtype animals, gsk3KI animals exhibited greater 
urinary phosphate and calcium clearances with higher excretion rates and lower plasma 
concentrations. Isolated brush border membranes from gsk3KI mice showed less sodium-
dependent phosphate transport and Na-phosphate co-transporter expression. Parathyroid 
hormone, 1,25-OH vitamin D levels, and bone mineral density decreased in gsk3KI
Coming to the conclusion of this study, we demonstrate that PKB/Akt/SGKdependent 
phosphorylation of GSK3 participates in the control of catecholamine release and thus in 
blood pressure regulation. Disruption of the inhibitory effect of PKB/Akt/SGK on GSK3 
 mice, 
suggesting a global dysregulation of bone mineral metabolism. Overexpression of GSK3 and 
the phosphate transporter NaPi-IIa in Xenopus oocytes decreased electrogenic phosphate 
transport compared with NaPi-IIa–expressing oocytes. Taken together, PKB/SGK 
phosphorylation of GSK3 increases phosphate transporter activity and reduces renal calcium 
and phosphate loss.  
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leads to enhanced catecholamine release and increase of blood pressure. We also demonstrate 
that Akt/PKB-dependent regulation of GSK3 participates in the control of renal tubular 
phosphate transport. Loss of Akt/PKB-dependent inhibition of GSK3αβ leads to renal 
phosphate wasting, which presumably contributes to or even accounts for the decrease of PTH 
release with resulting calciuria, decreased formation of 1,25-(OH)2 D3, and decreased 
mineralization of bone. These observations thus show a novel, powerful element in the 
regulation of mineral metabolism. 
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2. ABSTRAKT 
Die Glykogen-Synthase 3 (GSK3) spielt eine wichtige Rolle bei der Regulation zahlreicher 
Stoffwechselvorgänge und ist stromabwärts in verschiedenen intrazelluären Signalkaskaden 
anzutreffen (Insulin, Wachstumshormon, WNT, Tyrosinkinase-Rezeptor, G-Protein-Gekoppelte 
Proteine). Dabei werden verschiedene zelluläre Prozesse wie Glykogenstoffwechsel, 
Zellentwicklung, Gentranskription, Proteintranslation, Organisation des Zytoskeletts, 
Beeinflussung des Zellzyklus, Proliferation und Apoptose reguliert. Die Glykogen-Synthase 3 
wird inhibiert, indem sie durch die übergeordnete Protein kinase B (PK B/Akt) oder durch die 
Serum-und Glucocorticoid-Induzierbare Kinasen (SGK) phosphoryliert wird, die ihrerseits durch 
Wachstumsfaktoren unter Beteiligung der Phosphoinositide 3-Kinase (PI3K) aktiviert werden. 
Eine abnorm gesteigerte GSK3-Proteinexpression wird mit Krankheiten wie dem Diabetes 
mellitus 2, neurodegenerativen und affektiven Störungen in Verbindung gebracht, was zur 
Entwicklung pharmakologischer Hemmstoffe der GSK3 führte. Durch gezielte Mutation und 
Austausch der Serin-Phosphorylierungsstelle der GSK3 durch Alanin konnte ein genetisches 
Mausmodell geschaffen werden, bei dem die Inhibition der GSK3 durch die PI3K, PKB oder 
SGK aufgehoben ist (PKB/SGK-resistente GSK3, gsk3KI
Erste Erkenntnisse an gsk3
). Dies ermöglicht es, die 
physiologische und pathophysiologische Relevanz einer erhöhten GSK3-Aktivität zu 
untersuchen. 
KI
Der Blutdruck wurde mit der Schwanzplethysmographie ermittelt, die Herzfrequenz 
mittels EKG, die Plasma-Katecholamin-Konzentration mittels ELISA und die 
Vanillinmandelsäure als Abbauprodukt der Katecholamine aus dem Urin mittels HPLC. Der 
erhöhte Blutdruck der gsk3
- Mäusen zeigten einen im Vergleich zu Wildtyp-Mäusen 
signifikant höheren Blutdruck. Das erste Ziel der vorliegenden Arbeit bestand darin, die Ursache 
dafür herauszufinden. In weiteren Experimenten sollte zum anderen die Rolle der GSK3 bei der 
Regulation des tubulären Phosphattransports untersucht werden, da letzterer durch Insulin oder 
Insulin-like Growth Factor 1 stimuliert wird, die ihrerseits die GSK3 phosphorylieren und sie 
dadurch hemmen.  
KI- Mäusen ging mit einer erhöhten Herzfrequenz einher und wurde 
durch den alpha-Blocker Prazosin (1µg/g KG) und dem Gangleinblocker Hexamethonium (40 
µg/g KG) stärker gesenkt als in Wildtyp-Mäusen. Analog dazu senkte der Beta-blocker Atenolol 
(5 µg/g KG) die Herzfrequenz stärker in gsk3KI- Mäusen als in Wildtyp-Mäusen. Durch diese 
Behandlungen wurde der Unterschied zwischen gsk3KI- Mäusen und Wildtyp-Mäusen 
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hinsichtlich des Blutdrucks und der Heruzfrequenz aufgehoben. Die Plasma-Adrenalin- und –
Noradrenalin-Konzentration sowie die Ausscheidung des Vanillinmandelsäure im Urin waren in 
gsk3KI
Um die Rolle der GSK3 bei der Regulation des Phosphattransports zu erforschen, wurden 
gsk3
- Mäusen signifikant höher als in Wildtyp-Mäusen. Die Befunde weisen zum ersten Mal 
auf eine neuartige Funktion der PKB/SGK-abhängige GSK3-Signalübertragung hin, nämlich der 
Katecholamin-Sekretion. 
KI- Mäuse in Stoffwechselkäfigen untersucht und die renale Phosphat-Ausscheidung im 24 –
Stunden-Sammelurin bestimmt. Daneben wurden wichtige Regulatoren des Phosphat-Haushalts 
wie Parathormon oder 1,25-Dihydroxy-Vitamin D aus dem Plasma bestimmt. Zusätzlich wurde 
die Knochendichte mit einem hochauflösenden CT-Gerät für kleine Labortiere gemessen. 
Verglichen mit Wildtyp-Mäusen wiesen gsk3KI- Mäuse eine höhere Phosphat- und Kalzium-
Ausscheidung im Sammelurin auf und hatten eine niedrigere Phosphat- und Kalzium-
Konzentration im Plasma. Aus den Nieren isolierte Bürstensaum-Membranen wiesen eine 
geringere Expression des Na-gekoppelten Phosphat-Transporters auf, was mit einer geringeren 
Transportrate einherging. Die Konzentration von Parathormon und 1,25-Dihydroxy-Vitamin D 
sowie die Knochendichte waren in gsk3KI
Schlussfolgernd zeigt diese Arbeit, dass die PKB/SGK-abhängige Phopshorylierung 
der GSK3 in einem Mausmodell in vivo eine wichtige Rolle bei der Regulation des 
Blutdrucks und der Katecholamin-Freisetzung spielt und auch Knochen- und Mineral-
Haushalt beeinflusst. 
- Mäusen vermindert. In vitro-Versuche mit Oozyten, 
die den Na-gekoppelten Phosphat-Transporter exprimierten mit oder ohne gleichzeitige 
Expression von GSK3, zeigten einen reduzierten Phosphat-Transport bei Überexpression der 
GSK3. Die Ergebnisse zeigen, dass die Phosphorylierung der GSK3 durch die PKB/SGK den 
renalen Phosphattransport stimuliert und vor einer verminderten Knochendichte schützt. 
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°C Degree Celcius 
µg Microgram 
µm Micrometer 
1,25-(OH)2D 1,25-dihydroxy vitamin D3 3 
AA Amino Acids 
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AIDA Advanced Image Data Analyzer 
ANNOVA Analysis of variance 
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DRAQ-5 1,5-bis{[2-(di-methylamino) ethyl]amino}-4, 8-dihydroxyanthracene-9,10-
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eNOS endothelial nitric oxide synthase 
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FA Factor A 
FGF-23 Fibroblast Growth Factor 23 
Fig Figure 
FITC Flourescein Isothiocyanate 
FRAT Frequently Rearranged in Advanced T-Cell Lymphomas 
FZD Frizzled 
g Gram 
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Gly Glycine 
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mRNA Messenger RNA 
mTOR Mammalian Target of Rapamycin 
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Na Sodium Ion + 
NaCl Sodium Chloride 
NaPi-IIa Type IIa Na/Pi cotransporter 
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NFATc Nuclear Factor of Activated T Cells 
NF-kB Nuclear factor κ B 
ng Nanogram 
nl Nanolitter 
p70S6K p70 S6 Kinase 
p90RSK p90 Ribosomal S6 Kinase 
PBS Phosphate Buffered Saline 
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PFA Paraformaldehyde 
pg Picogram 
PGF Platelet Growth Factor 
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Pi Phosphate Ion 
PI3K Phosphoinositide 3-Kinase 
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PKA Protein Kinase A 
PKB Protein Kinase B,  also called Akt 
PKC Protein Kinase C 
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qRT-PCR Quantitative Real Time Polymerase Chain Reaction 
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s Second 
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S6 Small Subunit Ribosomal Protein S6 
Ser  Serine 
Ser21 Serine 21 
Ser9 Serine 9 
sFRP Soluble Frizzled-Related Protein 
SGK Serum and Glucocorticoid-Inducible Kinase 
SGK1 Serum and Glucocorticoid-Inducible Kinase 1 
SGK3 Serum and Glucocorticoid-Inducible Kinase 3 
TCFs T cell factors 
Thr Threonine 
TRPV5 Transient Receptor Potential Cation Channel V5 
Tyr Tyrosine 
UDP-glucose Uridine Diphosphate-Glucose 
VMA Vanilyl Mandelic Acid 
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7. INTRODUCTION 
Discovery and characterization of glycogen synthase kinase-3 (GSK3) 
The glycogen synthase kinase-3 (GSK-3) is a ubiquitously expressed, highly conserved 
multifunctional serine/threonine protein kinase found in all eukaryotes, which mediates the 
addition of phosphate molecules onto serine and threonine amino acid residues.  
It is also called Factor A (FA) for its ability to activate the MgATP-dependent form of the protein 
phosphatase PP1 called FC
It was first discovered about 32 years ago as one of several protein kinases that phosphorylated 
and inactivated glycogen synthase (Embi, N. et al., 1980), the enzyme which is involved in 
converting glucose to glycogen (glycogen biosynthesis). 
 (1-4). 
GSK3 acts as a downstream regulatory switch for various signaling pathways, including cellular 
responses to WNT, Growth Factors, Insulin, RTK (Receptor Tyrosine Kinases), Hedgehog 
pathways, and GPCR (G-Protein-Coupled Receptors) and is involved in a numerous signal 
transduction cascades involving cellular processes, ranging from glycogen metabolism, cell 
development, gene transcription, protein translation to cytoskeletal organization, cell cycle 
regulation, proliferation and apoptosis (Forde J.E., et al., 2007). GSK3 dysregulation has been 
implicated, in numerous diseases such as diabetes, inflammation, cancer, Alzheimer's and bipolar 
disorder (Doble B.W. et al., 2003). GSK3 negatively regulates insulin-mediated glycogen found 
in type II diabetics and obese animal models. Thus, its involvement in glucose metabolism 
increased scientific interest and from then, it has been extensively studied especially in the 
context of metabolic actions of insulin (Woodgett, J. R. et al., 2001). 
 
The glycogen synthase kinase-3 (GSK-3) was subsequently purified to homogeneity from 
skeletal muscle (Woodgett, J. R. et al., 1984) and from the molecular cloning study it is 
confirmed that there were two closely related isoforms, GSK3α (molecular mass B51 kDa) and 
GSK3β (molecular mass B47 kDa), which are expressed ubiquitously in mammalian tissues 
(Woodgett, J. R. et al., 1990 and Woodgett, J. R. et al., 1991).  
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Figure 7.1: Schematic representations of GSK-3α and GSK-3β isoforms. Blue arrow-heads indicate sites of serine 
and tyrosine phosphorylation. A glycine-rich N terminal domain of GSK-3α and a conserved kinase domain from 
both GSK-3α/β are highlighted  
 
These isoforms, GSK-3α and GSK-3β are encoded by two distinct genes which are located on 
chromosomes 19q13.1-2 and 3q13.3-q21. The catalytic domains of GSK3 (of both GSK-3α and 
GSK-3β isoforms) exhibit a high degree of sequence similarity, but the isoforms diverge in their 
N- and C-terminal sequences (Ciaraldi T.P., et al 2007; Markou T., et al. 2008). Using 
chromosomal mapping the exact cytological locations of these isoforms have been identified, i.e. 
GSK-3α is located at 19q13.2 and GSK-3β maps to 3q13.3 (Shaw P.C., et al. 1998). They exhibit 
about 98% homology in their kinase domains, but they share only about 36% identity in the last 
76 C-terminal amino-acid residues (figure 7.1) (Woodgett J.R., 1990).  
 
Molecular cloning of GSK-3 cDNAs allowed investigations of species representation of GSK-3 
genes. A genomic Southem blot of DNA isolated from yeast to humans probed with rat GSK-3 
demonstrated that the kinase is ubiquitous throughout the animal kingdom. Indeed, homologues 
of GSK-3 have been cloned from a number of eucaryotic species (see Table 1.1). GSK-3 proteins 
share a remarkable degree of identity within the catalytic domain. In vertebrates, the identity 
over this region is greater than 90 %. In invertebrates, there appears to be only one form of the 
enzyme which is most closely related to GSK3P. The Drosophila GSK-3 homologue, termed 
Zeste-white 3shagg~ shares 76 % overall identity with the rat GSK3P, and can be replaced 
functionally by this clone. GSK-3 family members have also been identified in a variety of plants 
(Arabidopsis, Petunin, alfalfa and Nicotinna) (see Table 7.1). The high degree of conservation 
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between GSK-3 proteins, as well as their ubiquitous representation, indicates a fundamental role 
of this kinase family in regulaiion of cellular processes 
Table7.1 Species representation of GSK-3 homologues 
Species Name Identity in the catalytic 
domain to rat GSK3β 
human GSK-3α, β 98 (Stambolic, V., and J. R. 
Woodgett., 1994) 
rat GSK-3α, β 100 (Woodgett, J. R. 1991) 
rabbit GSK-3β 100 (Wang, Q. M., et al., 1994) 
chicken GSK-3β 98 
Xenopus laevis Xgs k-3 92 (Pierce, S. B., and D. 
Kimelman., 1995) 
Drosophila melanogaster Zeste-white 
3shaggy 
88 (Siegfried, E., et al., 1992) 
Caenorhabditis elegans  78 
Dictyostelium discoideum GSK-3α 71 (Harwood, A. J., et al., 1995) 
Saccharomyces cerevisiae MCK1, MDS1, MRK1, 
ScGSK3 
44 -58 (Bianchi, M. W., et al., 
1993) 
Schizosaccharomyces 
pombe 
Skp1 65 (Plyte, S. E., et al., 1996) 
Arabidopsis thaliana ASK α, γ, ATK1 68-70 (Bianchi, M. W., et al., 
1994 and Jonak, C., et al., 1995)  
Petunia hybrida PSK4,6 70 (Decroocq-Ferrant, V., et al., 
1995) 
alfalfa MSK1,2,3 65-70 (Pay, A., et al., 1993) 
Nicotiana tabaccum Ntk1 56 (Einzenberger, E., et al., 
1995) 
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Although these isoforms, GSK-3α and GSK-3β are structurally similar, their expression patterns, 
substrate preferences and cellular functions are different (Woodgett J.R., 2001; Doble and 
Woodgett J.R., 2003).  It has been reported by Hoeflich K.P., et al. 2000 that, mice after carrying 
homozygous deletions of exon 2 of the GSK-3β isoform suffer from major liver degenerations 
which was due to extensive hepatocyte apoptosis, leading to death of the embryo at day 16. Thus 
GSK-3α isoform was unable to compensate for the loss of GSK-3β. From this Hoeflich K.P., et 
al., concluded that the degenerative liver phenotype develops specifically from the loss of GSK-
3β isoform (Doble and Woodgett 2003).  
 
Regulation of gsk3 by insulin and growth factors 
GSK-3 is, unlike most other protein kinases, active in the resting state and deactivated by 
phosphorylation. The most well defined mechanism of GSK-3 regulation is the phosphorylation 
of Serine 9 (Ser9) in GSK-3β and Ser21 in the GSK-3α isoform. This is in response to hormones 
such as insulin, endothelial growth factor and platelet growth factor.  
It was first suggested in 1978 that the inhibition of GSK3 might underlie the insulin-induced 
dephosphorylation and thereby activation of glycogen synthase (Cohen, P., et al., 1978). This 
was confirmed and reported that insulin stimulates the dephosphorylation of glycogen synthase 
at the sites where it was phosphorylated by GSK3 (Parker, P. J., et al., 1983) and subsequently 
that insulin acutely inhibits GSK3 (Welsh, G. I. et al., 1993 and Welsh, G. I. et al., 1998). The 
inhibition of GSK3 by insulin was shown to result from its phosphorylation at an N-terminal 
serine residue (Ser21 in GSK3α and Ser9
Thus, insulin stimulates glycogen synthesis by inhibiting GSK-3 and dephosphorylation and 
thereby activation of glycogen synthase (figure 7.2b). PKB/Akt (PI3K pathway), some isoforms 
of protein kinase C (PKC), PKA, p90RSK and p70S6 kinase may all be involved in  
phosphorylation of GSK-3, thus inactivating it (Cohen, P., et al., 1997 and Cohen, P. et al., 
1999). 
 in GSK3β) and that this is catalysed by protein kinase B 
(PKB; also called Akt) (Cross, D. A., et al., 1995). 
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Figure 7.2a 
 
Figure 7.2b 
Figure 7.2 Regulation of glycogen metabolism by glycogen synthase kinase 3 (GSK3).  
(a) Casein kinase 2 (CK2) phosphorylates a priming Ser residue in the C terminus of glycogen synthase (Ser657 in 
the muscle isoform of Homo sapiens) to initiate a relay of GSK3-catalysed phosphorylations, as described in the 
text.  
(b) Glycogen synthase activity is regulated by a phosphorylation–dephosphorylation cycle. In the preprandial state, 
plasma insulin concentrations are low and GSK3 is active. GSK3 phosphorylates glycogen synthase and converts it 
to the less-active (glucose-6-phosphate (G6P) dependent) form, thus inhibiting glycogen synthesis. When plasma 
insulin concentrations rise after feeding, insulin promotes phosphorylation of GSK3 and inhibits GSK3 activity. 
Dephosphorylation of glycogen synthase by protein phosphatases (GS phosphatase) subsequently increases the 
activity of glycogen synthase and promotes glycogen synthesis.  
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The eukaryotic protein synthesis initiation factor 2B (eIF2B), play important role in synthesis of 
eukaryotic protein. GSK3 catalyses the phosphorylation and inhibition of eIF2B with subsequent 
inhibition of protein synthesis. Thus insulin by inhibiting GSK3, stimulates the 
dephosphorylation and activation of eIF2B (Welsh, G. I. et al., 1993 and Welsh, G. I., et al., 
1998). Insulin also suppose to stimulates protein phosphatase(s) that dephosphorylate(s) and 
thereby activates eIF2B, contributing to increased rate of protein synthesis. 
 
Figure 7.3 Insulin stimulates glycogen and protein synthesis via the inhibition of GSK3 
The binding of insulin (yellow) to its receptor (green) in liver, adipose tissue and muscle, triggers the 
phosphorylation of IRS proteins (red) and their recruitment to the plasma membrane. The IRS proteins in turn 
become tyrosine-phosphorylated, recruiting PI 3-kinase (PI3K, purple) to the membrane, where it produces the 
second messenger PtdIns(3,4,5)P3 (PIP3). This molecule binds to PDK1 (dark blue) and PKB (pink), co-localizing 
them at the plasma membrane and allowing the former to activate the latter. Active PKB th inhibits GSK3 (dull 
blue) by phosphorylating Ser21 (GSK3α) and Ser9
partial dephosphorylation, thereby increasing their activity and hence stimulating glycogen (orange) and protein 
(blue, bottom right) synthesis. 
 (GSK3β). As a result, the residues on glycogen synthase (pale 
yellow) and the e-subunit of eukaryotic initiation factor 2B (eIF2B, lilac) that are targeted by GSK3 undergo a 
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In addition, a downstream kinase of the classical mitogen-activated protein kinase (MAPK) 
cascade, known as MAPK-activated protein kinase-1 (MAPKAP-K1, also called RSK), 
phosphorylates GSK3 at Ser9/Ser21 
Thus in brief, 
and thereby inhibit it. Thus growth factors and other signals 
activating the MAPK pathway, can also inhibits GSK3.  
1) Insulin inhibits GSK3 via the PI 3-kinase-dependent/PKB pathway. 
2) Signals such as tumour-promoting phorbol esters inhibit GSK3 via the classical MAPK 
cascade. 
3) Other growth factors, such as epidermal growth factor (EGF), can inhibit GSK3 by both 
pathways (figure 7.3) (Shaw, M. et al., 1999).  
  
The protein kinase such as p70 ribosomal S6 kinase-1 (S6K1) phosphorylates GSK3 at Ser9 / 
Ser21 and thereby inhibits it (Cross, D. A., et al., 1994). The amino acids thus activates S6K1 via 
mTOR, hence immunosuppressant drug such as rapamycin, which inactivates mammalian target 
of rapamycin (mTOR), a protein kinase required for the activation of S6K1, suppresses the 
inhibition of GSK3 induced by amino acids(figure 7.4). The phosphorylation of GSK3 at Ser9 / 
Ser21
 
 also suppose to be induced by incubating cells with cAMP-elevating agents or cell-
permeant cAMP analogues (Fang, X., et al., 2000 and Li, M., et al 2000).  
 
 
 
 
 
 
 
Introduction 
 
25 
 
 
 
Figure 7.4 Several signalling pathways inhibit GSK3 
GSK3 can be inhibited via several signal-transduction pathways, namely the PI 3-kinase - PKB pathway (green), the 
classical MAPK (yellow) cascade, where MAPKAP-K1 (also called RSK) inhibits GSK3, and the mTOR pathway, 
where p70 S6 kinase (S6K, lilac) inhibits GSK3 (purple). Insulin exerts its effects via the PI3K-PKB pathway, 
tumour-promoting phorbol esters via the classical MAPK cascade and amino acids via mTOR. However, some 
signals, such as EGF, can use more than one pathway to inhibit GSK3. The cell-permeant inhibitors indicated in the 
figure block one pathway selectively and have been critical in establishing the roles of these pathways in the 
regulation of GSK3 activity. Li+ ions, which inhibit GSK3 relatively selectively in vitro, have been useful in 
identifying potential roles for GSK3 in cells. More potent cell-permeant inhibitors of GSK3, such as SB 216763 and 
SB 415286, have been developed recently. 
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GSK3 as a key component of the WNT
The Wnt family of secretory glycoproteins is one of the major families of developmentally 
important signaling molecules. They were initially characterized for their roles in regulating 
embryonic development and tumorigenesis. Studies in the past decade have implicated Wnt 
signaling in a diverse range of physiological and pathophysiological processes, including bone 
development, angiogenesis, vasculature remodeling, myogenesis, adipogenesis, stem cell 
renewal and differentiation, and lipid and glucose metabolism.  
 signaling Pathway 
The Wnt proteins are defined based on sequence homology to the original Wnt members: mouse 
WNT1 (originally called int-1) and Drosophila melanogaster Wingless (Wg). Mutations in Wnt 
genes exhibit a variety of intrinsing phenotypes in the mouse, Caenorhabditis elegans, and 
Drosophila, indicating that Wnt proteins function in diverse developmental processes. Numerous 
studies have established a canonical signaling pathway that leads to β-catenin stabilization, via 
Wnt signalling (Fig. 1.5). In the absence of Wnt, a number of proteins, including AXIN, 
adenomatous polyposis coli (APC), GSK3, casein kinase Iα (CKIα)), and β-catenin, form a 
complex (referred to as the β-catenin destruction complex), in which β-catenin is phosphorylated 
by CKIα) and GSK3. This phosphorylation event targets β-catenin for proteasome-mediated 
proteolytic degradation. When Wnt proteins bind cell-surface receptors frizzled (FZD) and 
lipoprotein receptor-related protein (LRP) 5/6, GSK3-dependent β-catenin phosphorylation is 
suppressed through a mechanism that requires the scaffold protein dishevelled (DVL), resulting 
in stabilization of β-catenin (Figure 7.5). Stabilized β-catenin enters the nucleus and interacts 
with transcriptional regulators, including lymphoid enhancing factor-1 (LEF1) and T cell factors 
(TCFs), to activate gene transcription. Mammals express 19 Wnt genes as well as many Wnt 
antagonists. 
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Figure 7.5 Schematic representation of simplified canonical Wnt signaling pathways 
There are generally two pools of β-catenin in cells. One pool is associated with cadherins, whereas the other is 
degraded in the absence of Wnt by the β-catenin destruction complex. Wnt binds two cell surface receptors (LRP5/6 
and FZD) and leads to phosphorylation at least of Thr-1479 by CKIγ, Ser-1490 by GSK3, and Thr-1493 by yet to be 
identified CKs on LRP6. These phosphorylation events are required for AXIN recruitment and β-catenin 
stabilization. Stabilized β-catenin enters the nucleus and activates gene transcription activation. Two of the Wnt 
antagonists, Dickkopf (DKK) and soluble frizzled-related protein (sFRP), are also shown. 
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Substrates of GSK3: general points 
GSK3 preferentially phosphorylates substrates on Ser/Thr residues in a ‘relay’ fashion. A 
‘priming’ phosphorylation on a Ser/Thr residue is catalysed by a protein kinase distinct from 
GSK3. This increases the rate of phosphorylation by GSK3 at a Ser/Thr residue -4 to the priming 
phosphorylation (that is, the fourth residue lying N-terminal to the priming phosphorylation, for 
example, Ser-Xaa-Xaa-Xaa-Ser(P)). The first GSK3-mediated phosphorylation may serve to 
prime a second phosphorylation at any Ser/Thr residue lying -4 relative to this. The extent of 
such relays may be limited and consist of only two residues as in the transcription factor c-Jun 
(residues 239 and 243 for H. sapiens c-Jun, the former being the GSK3 site and the latter being 
the priming site;(Cohen and Goedert, 2004). In contrast, a relay system of up to five Ser residues 
between residues 641 and 657 (the latter representing the priming site; Figure 7.2a) potentially 
operates in the N terminus of H. sapiens muscle glycogen synthase. Individual priming 
phosphorylations are catalysed by one of a number of different protein kinases, including casein 
kinases (for example, casein kinase 2 catalyses the priming phosphorylation in glycogen 
synthase), PKA, cyclin-dependent protein kinases, MSKs and dual specificity tyrosine 
phosphorylated and regulated kinases (Cohen and Goedert, 2004). The crystal structure of 
GSK3b accounts for the requirement for a priming phosphorylation and for the inhibitory effect 
of phosphorylation of Ser9 (Dajani et al., 2001; Frame et al., 2001). Thus, GSK3b (Arg96) 
interacts with the priming phosphate in a substrate, orientating it for phosphorylation at the -4 
position. Phosphorylation of GSK3b(Ser9) causes an intramolecular interaction with Arg96, and 
the N terminus of the enzyme then serves as a pseudosubstrate to block both the binding site for 
the priming phosphate and access of any substrate to the catalytic pocket. 
Criteria needed to establish that a protein is a Physiological substrate for gsk3 
Following are the criteria that need to be met before a protein can truly be regarded as a 
physiological substrate for GSK3 (figure 7.6): 
1. The substrate should be phosphorylated by GSK3 in vitro at the same residue(s) as that 
occurred in vivo. 
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2. Phosphorylation should get abolished by mutagenesis of this (these) site(s) to (a) non-
phosphorylatable residue(s). 
 
3. The signals known to inhibit GSK3 should decrease the phosphorylation of the 
endogenous protein in cells. 
 
4. Upon incubation of cells with cell permeant inhibitors of GSK3, dephosphorylation of 
endogenous proteins at the relevant site(s) should occur. 
 
5. Phosphorylation of the residues targeted by GSK3 should affect the function of the 
protein in a manner consistent with physiological effects of the agonist(s) that regulate(s) 
GSK3 activity. 
 
6. Phosphorylation of the protein at the GSK3 site(s) should not occur in cells that carry 
targeted disruptions of the genes encoding GSK3, and be restored when GSK3 is 
replaced. 
 
7. Dephosphorylation of the protein at the GSK3 site(s) should not occur in response to the 
appropriate signal in cells that do not express one of the protein kinases that lies upstream 
of GSK3; for example, in PDK1−/− embryonic stem cells, PKB, MAPKAP -K1 and p70 
S6 kinase are not activated, and GSK3 is not inhibited, in response to IGF-1 or 
tumourpromoting phorbol esters (Williams, M. R., et al., 2000). 
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Table 7.2 Proteins reported to be substrates of GSK3 (Sheelagh Frame and Phillip Cohen, 
2001) 
Putative 
substrate 
Biological process Function proposed for phosphorylation 
Glycogen 
synthase 
Glycogen synthesis  Inactivates 
eIF2B Protein synthesis Inactivates 
ATP citrate lyase Fatty acid synthesis None 
Axin Wnt signalling Stabilizes protein and recruits b-catenin 
b-Catenin Wnt signalling/adhesion Targets for degradation 
APC Wnt signalling Facilitates binding of b-catenin to APC and 
decreases binding of APC to microtubules 
MUC1/DF3 Glycoprotein Decreases affinity of MUC1 for b-catenin 
Cyclin D1 Cell division cycle Nuclear export and targets for degradation 
Jun Transcription factor Inhibits DNA binding and transactivation 
Myc Transcription factor Targets for degradation 
NFATc Transcription factor Promotes nuclear export, inhibits DNA binding 
C/EBPa Transcription factor None 
C/EBPb Transcription factor Inhibits DNA binding and transactivation 
CREB Transcription factor Enhances transcriptional activity 
MITF Transcription factor Enhances binding to the tyrosinase promoter 
HSF-1 Transcription factor Inhibits DNA binding and transactivation 
Tau Microtubule-binding 
protein 
Inhibits binding to microtubules 
MAP1B Microtubule-binding 
protein 
Maintains microtubular instability 
Presenilin-1 Transmembrane protein Disposal of excess C-terminal fragments of 
presenilin, generated by endoproteolytic processing 
Insulin receptor 
substrate 1 
Insulin signalling Inhibits insulin receptor signalling 
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Table 7.2 shows how well these criteria have been met for proposed proteins to act as GSK3 
substrates, few of them met first criterion. There is sufficient evidence stating that GSK3 which 
phosphorylate particular proteins in cells is based on the finding that Li+ affect the function of 
the protein in a manner consistent with dephosphorylation having occurred, but this is not 
applicable to all cases. On the contrary, Li+
Proposed substrates of GSK3 
 being a relatively specific inhibitor of GSK3, it can 
also inhibit a few other protein kinases (Davies, S. P., et al., 2000) too.  It is however important 
to shown that the effects of the drug disappear when a drug resistant mutant is overexpressed or 
replaces the endogenous wild-type enzyme (Brown, E. J.,et al., 1995, and Eyers, P. A., et al., 
1998). But none of the substrates meet the sixth or seventh criteria.    
 
Figure 7.6 Proposed substrates of GSK3 
Putative substrates are colour-coded according to their proposed function in the cell ; transcription factors 
(mauve), enzymes that regulate metabolism (blue), proteins bound to microtubules (turquoise), scaffold proteins 
(orange), or components of the cell division cycle machinery (pink) or involved in cell adhesion (yellow). The 
evidence that these proteins are substrates of GSK3 is summarized in Table 7.2. Transcription factors are 
subdivided into those that are inhibited (®), activated (­) or unaffected by the phosphorylation by GSK3. A complex 
consisting of GSK3, Axin, APC and b-catenin (depicted by ellipses) is critical for regulating embryogenesis. The 
phosphorylation of cyclin D1 by GSK3, which is thought to occur in the nucleus of the cell, promotes its nuclear 
export and degradation. Presenilin-1 is reported to act as a scaffold, which facilitates the phosphorylation of tau by 
GSK3. 
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Preclinical efficiency of GSK-3 inhibitors 
It was nearly 50 years after the discovery of the unique properties of lithium in manic-depression 
illness (bipolar affective disorder) that GSK-3 was identified as one of its main targets (Klein, 
P.S., et al., 1996, Phiel, C.J. and Klein, P.S., 2001, and Jope, R.S., 2003).   Since then, lithium 
has been used widely as a pharmacological inhibitor of GSK-3, despite the millimolar 
concentrations that are required to affect GSK-3 in living cells. The definitive mood-stabilizing 
properties of lithium, the insulin-mimetic properties of GSK-3 inhibition and the GSK-3-
dependent abnormal phosphorylation of Tau and production of amyloid-b in Alzheimer’s disease 
have stimulated the search for potent, selective inhibitors of GSK-3. At present ≥30 inhibitors 
have been described, some with IC50
Table 7.3 GSK3 inhibitors (Bradley W.Doble and James R. Woodgett, 2003) 
 values in the nanomolar range. These GSK-3 inhibitors 
have been found beneficial in various diseases and health conditions (Table 7.3).  
Drug type 
Specific drug 
examples 
Mode of action 
Clinical effects/effects in cell 
culture 
Aloisines 
Aloisine A, 
Aloisine B 
ATP-competitive Inhibits cell proliferation 
Beryllium N/A 
Competes for Mg2+ and 
ATP 
No data 
Bivalent zinc N/A 
Undetermined; does not 
compete for substrate 
Insulin-mimetic 
Hymenialdisine 
Dibromo- 
hymenialdisine 
ATP-competitive 
Suppresses inflammation; inhibits 
tau phosphorylation 
Indirubins 
5,5¢-dibromo-
indirubin 
ATP-competitive 
Anti-mitotic; anti-tumoural; inhibits 
tau phosphorylation 
Lithium N/A Competes for Mg2+ 
Mood stabilization; prevents 
polyglutamine toxicity in 
Huntington’s disease 
Maleimides 
Ro 31-8220, SB-
216763, SB-
415286 
ATP-competitive 
Insulin-mimetic; prevention of death 
in culture neuronal 
Muscarinic 
agonists 
AF102B, AF150 Unclear Inhibits tau phosphorylation 
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The role of GSK3ß in cardiovascular system 
Insulin signaling includes stimulation of phosphoinositide (PI) 3 kinase with subsequent 
activation of protein kinase B (PKB/Akt) and the serum and glucocorticoid inducible kinase 
(SGK) isoforms [12, 16]. PKB/SGK regulate  a wide variety of target proteins including the 
glycogen synthase kinase GSK, which is phosphorylated and thus inhibited by PKB (Cross HR,et 
al., 1995 and Shaw M, et al., 1997) and SGK . 
In order to elucidate the physiological impact of PKB/SGK-dependent regulation of GSK3, gene 
targeted mice were generated, in which the serine within the PKB phosphorylation site was 
replaced by alanine (GSK3α21A/21A, GSK3ß9A/9A) thus yielding resistance of GSK3 to inactivation 
by PKB/SGK (McManus EJ, et al., 2005). Expectedly, the knockin mice carrying these mutations 
(gsk3KI
The present study explored whether the differences of blood pressure between gsk3
) are resistant to the effect of insulin on muscle glycogen synthase (McManus EJ, et al., 
2005). Furthermore, the mice are resistant to isoproterenol induced heart failure (Webb IG, et al., 
2010). Recent physiological evaluation of those mice revealed an increase in blood pressure 
(Boini KM, et al., 2008). The enhanced blood pressure could be lowered by the α-adrenergic 
antagonist prazosine (Boini KM, et al., 2009), pointing to a role of the sympathetic nerve system. 
It was also shown, that gsk3ki mice exibit a hyperactive behaviour (Ackermann TF, et al., 2010). 
KI 
mice and wild type mice (gsk3WT) were dependent on adrenergic stimulation and paralleled by 
differences in catecholamine release. To this end, blood pressure was determined prior to and 
following administration of the α-adrenergic antagonist prazosine (Kobinger W., 1984) or the 
ganglion blocker hexamethonium (Randall WC,et al., 1998), as well as blood pressure and 
cardiac rate prior to and following administration of the ß-blocker atenolol (Ram CV., 2010). 
Moreover, catecholamine plasma levels as well as urinary excretion of the catecholamine 
metabolite vanilylmandelic acid (Goldstein DS, et al., 2003) were determined in gsk3KI and in 
gsk3WT
 
 mice.   
The role of GSK3ß in renal tubular calcium and phosphate transport 
The kidneys play a central role in the regulation of mineral homeostasis by mediating 
excretion or reabsorption, respectively, of phosphate, calcium, and magnesium. Phosphate 
Introduction 
 
34 
 
reabsorption occurs in the proximal tubule and is mediated by at least three distinct sodium-
dependent phosphate cotransporters, namely NaPi-IIa (SLC34A1), NaPi-IIc (SLC34A3), and Pit-
2 (SLC20A2), located in the apical brush border membrane (Biber J, et al., 2009; Murer H,et al., 
2004 and Villa-Bellosta R, et al., 2009).  
Renal phosphate reabsorption is regulated by various factors including dietary phosphate intake, 
acid-base status, and various hormones, such as parathyroid hormone (PTH), 1,25-(OH)2 
vitamin D3, FGF-23, insulin, and IGF1(Allon M., 1992; DeFronzo RA, et al., 1976; Feld S, et 
al., 1996; Jehle AW, et al., 1998; Murer H, et al., 2000; Nowik M, et al., 2008 and Picard N, et 
al., 2010). Active calcium reabsorption is mediated by the TRPV5 calcium channel expressed in 
the luminal membrane of the distal convoluted tubule and connecting tubule (Boros S,et al., 
2009; Hoenderop JG, et al., 20005 and Woudenberg-Vrenken TE, et al., 2009).  The expression 
and activity of TRPV5 is regulated by several factors similarly regulating renal phosphate 
transport, such as dietary calcium intake, PTH, klotho, acid-base status, and 1,25-(OH)2
The intracellular signaling cascades mediating the effects of these hormones on renal 
phosphate transporters are still incompletely understood. Signaling of the phosphaturic hormone 
PTH involves the protein kinases A and C and ERK1/2, (Bacic D, et al., 2003) leading to the 
internalization and degradation of the NaPi-IIa cotransporter in the mouse and rat kidney (Bacic 
D, et al., 2006). Signaling mediating the stimulating effect of insulin and IGF1 on renal 
phosphate reabsorption (Allon M., 1992; DeFronzo RA, et al., 1976 and Feld S, et al., 1996) has 
remained ill-defined. Signaling of insulin includes stimulation of the PI3 kinase pathway with 
subsequent activation of protein kinase B (PKB/Akt) and the serum- and glucocorticoid-
inducible kinase (SGK) isoforms (Hawkins PT, et al., 2006 and Lang F, et al., 2006). Both, PKB 
(Cross HR, et al., 1995 and Shaw M, et al., 1997) and SGK (Sakoda H, et al., 2003 and Wyatt 
AW, et al., 2006) isoforms are known to phosphorylate and thus to inhibit the glycogen synthase 
kinase GSK3. However, nothing is known about the regulation of epithelial phosphate and Ca
 vitamin 
D3 (Boros S,et al., 2009; Hoenderop JG, et al., 20005 and Woudenberg-Vrenken TE, et al., 
2009). The role of insulin and IGF1 has remained controversial (DeFronzo RA, et al., 1975 and 
Hoskins B, et al., 1984).  
2+ 
transport by GSK3. 
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This study aimed to define the role of PKB/SGK-dependent regulation of GSK3 in the 
control of renal tubular calcium and phosphate transport. To this end, renal mineral excretion 
was analyzed in gene-targeted gsk3KI mice. In those mice (gsk3KI), GSKα and GSK3β are 
resistant against inactivation by PKB/SGK (McManus EJ, et al., 2005). As shown before, gsk3KI
 
 
mice are resistant to the effect of insulin on muscle glycogen synthase (McManus EJ, et al., 
2005).  
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8. AIMS OF THE STUDY 
 
The aims of the present study were to determine: 
 
1. Whether, the over expression of GSK3 (as in GSK3 KI
 
 mouse model) is the underlying 
cause of elevated blood pressure. If so, then whether this elevated blood pressure is 
dependent on adrenergic stimulation and paralleled by enhanced catecholamine release. 
2. Whether, PKB/SGK phosphorylation of GSK3 increases phosphate transporter activity 
and reduces renal calcium and phosphate loss. Thus thereby, whether overexpression 
of GSK3 and the phosphate transporter NaPi-IIa in Xenopus oocytes decrease 
electrogenic phosphate transport and decrease renal tubular calcium and phosphorus 
reabsorption. Thus to show novel role of PI3/PKB/Akt/SGK-resistant GSK3 in the 
control of renal tubular calcium and phosphate transport. 
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9. MATERIALS AND METHODS 
9.1 Materials 
9.1.1 Chemicals 
 
1,25-(OH)2D3 Kit (IDS, Boldon, UK) 
Agarose-Gel-Elektrophorese-Chamber (Biorad, München, Germany) 
Alkaline Phosphatase (Promega Gmbh., Mannheim, Germany)  
Aqua Ad Injectabili (Ampuwa, Niefern, Germany) 
Atenolol (Sigma-Aldrich, Hannover, Germany) 
Beta-Mercaptoethanol (Sigma-Aldrich; Hannover, Germany) 
Bio-Rad Protein Assay kit (Bio-Rad, Hercules, CA) 
Catecholamine ELISA kit (Labor Diagnostika Nord, Nordhorn, Germany) 
Creatinine Kit Jaffe’s Reaction (Sigma, St. Louis, MO) 
Diethylether (Carl Roth, Karlsruhe, Germany) 
DRAQ-5 Dye (1:1000, Biostatus, Leicestershire, UK). 
Goat anti-Rabbit or Donkey anti-Mouse Antibodies (1:5000)  
GSK3 Antibody (1:100, Cell Signaling, USA) 
GSK3β cDNA(Deutsches Ressourcenzentrum fur Genomforschung, Berlin, Germany) 
Haematoxylin and Eosin (Carl Roth, Karlsruhe, Germany) 
Hexamethonium hzdrochloride (Sigma-Aldrich, Hannover, Germany) 
Horseradish Peroxidase (GE Healthcare, Formerly Amersham Biosciences, US)  
Hydrochloric acid (6 M HCl) 
Isoflurane (Essex, Munich, Germany) 
Mannitol (VWR International, BVBA, Belgium) 
Milk powder 5% (Carl Roth, Karlsruhe, Germany) 
Mouse Monoclonal anti-β-actin Antibody (42 kD; Sigma; 1:5000) 
Nitrogen Liquide (Linde, Wiesbaden, Germany) 
Normal Goat Serum 5%  
Para formaldehyde (Carl Roth, Karlsruhe, Germany) 
PBS tablets (Invitrogen corporation for Invitrolaboratory, UK) 
Parafine (Merck, Darmstadt, Germany) 
Parathormone ELISA Kit (Immunotopics, San Clemante, CA) 
Phosphate Diagnostic Kit (Roche Diagnostics, Mannheim, Germany) 
Polyacrylamide Gels 8% (Carl Roth, Karlsruhe, Germany) 
Polyvinylidene Fluoride Membranes (Immobilon-P; Millipore, Bedford, MA) 
Potassium chloride 3M (3MKCl) (Carl Roth, Karlsruhe, Germany) 
Prazosine (Sigma-Aldrich, Hannover, Germany) 
ProLong Gold Antifade Reagent (Invitrogen, UK) 
Rabbit Polyclonal anti-NaPi-IIa (1:6000),  
Rabbit polyclonal anti-NaPi-IIc (1:10,000)  
Rabbit polyclonal anti-Pit-2 (1:3000)  
Secondary FITC Goat Anti-Rabbit Antibody (1:1000, Invitrogen, UK). 
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Silicon Spray (Dr. Schumacher GmbH, Malsfed, Germany) 
Sterilium (BODE, Chemie, GmbH, Hamburg, Germany) 
Triton X-100 (Roche Diagnostics, Mannheim, Germany) 
Ttrisodium PFA (6 mM)  
Tween 20 (Böhringer Ingelheim, Manheim, Germany) 
 
Diets (Altromin, Lage, Germany) 
Low-Phosphate Diet C1047 [0.24% Na+, 0.71% K+, 0.95% Ca2+, 131mg/kg phosphorus] 
Standard Diet C1310/1314 [0.24% Na+, 0.71% K+, 0.95% Ca2+] 
Control Diet C1000 [0.24% Na+, 0.71% K+, 0.95% Ca2+, 7523 mg/kg phosphorus] 
 
 
9.1.2 Solutions 
 
Phosphate Buffered Saline (PAA Laboratories GmbH., Germany) 
RLT-Buffer (Qiagen, Basel, Switzerland) 
Trisbuffer (pH 8.5) (Sigma-Aldrich, Hannover, Germany) 
 
Phosphate Buffered Saline 
PBS was prepared from ready soluble PBS pellets (PAA laboratories) according to 
manufactureres instruction.  
 
4% Paraformaldehyde  
4% PFA was prepared by dissolving PFA powder (Carl Roth, Karlsruhe, Germany) at 60^°C in 
PBS overnight. PFA was aliquted and stored at -20°C until use without refreezing. 
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9.1.3 Instruments/Equipments 
 
Non-Invasive Blood Pressure System (NIBP) (IITC life sciences, Los Angeles, United States of 
America) 
Power Labs Dual Bio Amps (ML135) (ADInstruments GmbH., Germany) 
Power Labs Dual Bio Cable (Dual Bio to 5 Alligator, 1 m) (ADInstruments GmbH., Germany) 
Small Animal Anesthesia Machine (Isoflurane Vaporizer) (Rothacher medical GmbH, Bern 
Switzerland) 
Metabolic Cages (Techniplast, Hohenpeissenberg, Germany) 
High Pressure Liquid Chromatography (HPLC) (Jasco Labor-u. Datentechnik GmbH., Germany) 
Microtome (Thermo Scientific) 
Zeiss LSM 5 EXCITER Confocal Laser Scanning Microscope (Carl Zeiss MicroImaging GmbH, 
Germany) 
Flame Photometry (ELEX 6361; Eppendorf) 
Dri-Chem Clinical Chemistry Analyzer (FUJI FDC 3500i; Sysmex, Norsted, Germany) 
Small Animal Computed Tomography (MicroCAT-II, Siemens Preclinical Solutions) 
qRT-PCR - ABI PRISM 7700 Sequence Detection System (Applied Biosystems) 
DIANA III-Chemiluminescence Detection System (Raytest, Straubenhardt, Germany) 
 
9.1.4 Software 
 
 
AD ECG Analysis Module (ADInstruments GmbH, Germany) 
Advanced Image Data Analyzer AIDA, Raytest  
Blood Pressure Computerized Data Acquisition Software (PowerLab 400 and Chart 4, 
Colorado Springs, Colorado Springs, USA) 
Data Link Version 1.0.0 (Herbert &Scheneider Software & CAM, Siglingen, Germany) 
GraphPad Instat Version 3.00 (GraphPad Software Inc., San Diego, USA) 
Image J Software  
Inveon Research Workplace software (Siemens Preclinical Solutions) 
Microsoft Office 2007-Excel, Word, PowerPoint (Microsoft GmbH., Remscheid,Germany) 
Microsoft Windows 95 (Microsoft GmbH., Remscheid, Germany) 
Sigma Plot Version 7.0 (Systat Software Inc., Erkrath, Germany) 
Zeiss Axiovision Software (Zeiss AG, Oberkochen, Germany) 
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9. MATERIALS AND METHODS 
9.2 Methods 
GSK3 and Catecholamine  
All animal experiments were conducted according to the guidelines of the American Physiological 
Society as well as the German law for the welfare of animals and were approved by local 
authorities. 
 Mice were generated, in which the codon encoding Ser9 of GSK3ß gene was changed to 
encode nonphosphorylatable alanine (GSK3ß9A/9A), and simultaneously the codon encoding Ser21 
of GSK3α was changed to encode the nonphosphorylatable  GSK3α21A/21A thus yielding the 
GSK3α/β21A/21A/9A/9A double knockin mouse (gsk3KI) as described previously (McManus EJ et al., 
2005). The mice were compared to corresponding wild type mice (gsk3WT
Mice were fed a control diet and had free access to tap drinking water. Where indicated, 
animals were treated with intraperitoneal injection of α-adrenoreceptor antagonist prazosine (1 µg/g 
b.w.), ganglion blocker hexamethonium (40 µg/g b.w.) or β-adrenergic receptor antagonist atenolol 
(5 µg/g b.w.). Drugs were administered at intervals of more than 48 hrs during the afternoon.  
) at 4 months of age. 
 
9.2.1 ECG recordings 
Mice were sedated by isoflurane inhalation [Janssen et al., 2004]. Induction of isoflurane 
anaesthesia was facilitated by 5% isoflurane, which was maintained by 1-1.5% isoflurane. ECG 
recording were obtained by Bio Cable- (Dual Bio to 5 Alligator, 1 m with built-in Dual Bio 
Amps (ML135) at a sampling rate of 1 kHz, high Pass 10kHz, low pass 500 Hz) connected to 
PowerLabs. For electrical conduct, AgCl electrodes were bathed in 1M KCl solution on a 24 
well plate suitbale to the position of the paws. After induction of anaesthesia, the mouse was 
positioned on the plate and the extremities bathed in the KCl solution. 
The recordings were analysed by AD ECG Analysis Module (Adinstruments company). After 
baseline readings, atenolol (5 µg/g b.w.) was administered and heart rate was monitored for 10 
minutes. 
Recording of ECG in two derivations: I (right front paw – left front paw) and II (right front paw 
– left leg). 
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9.2.2 Blood pressure determinations 
 Systolic arterial blood pressure was determined by the tail-cuff method (IITC 
life sciences, Los Angeles, United States of America). As reviewed earlier (Meneton P., et al., 
2000), the tail cuff approach to determine arterial blood pressure requires certain precautions to 
reduce the stress of the animals. Animals are placed in a clean plastic animal holder (IITC life 
sciences, Los Angeles, United States of America). The tail is positioned inside a tail cuff with a 
photoelectric sensor use light and photo sensors for pulse detection. The ambient temperature is 
kept constant at 29 °C. The animals were accustomed to the tail cuff procedure by simulating the 
measurements without recording of blood pressure. Mice were accustomed to the tail cuff 
procedure for 1 week. Provided precautions  were taken to reduce the stress of the animals, 
including appropriate training of the mice over multiple days, prewarming to an ambient 
temperatu re of 29°C, measurement in a quiet, semi darkened and clean environment, and 
performance of the measurements by one person and during a defined day time, when blood 
pressure is stable (between 1-3 
In a second study group blood pressure was measured by tail cuff method during 
isoflurane anaesthesia (1.5% isoflurane). Blood pressure was measured after induction of 
anaesthesia for 10 minutes followed by intraperitoneal injection of α-adrenoreceptor antagonist 
prazosine (1 µg/g b.w.), ganglion blocker hexamethonium (40 µg/g b.w.) or β-adrenergic 
receptor antagonist atenolol (5 µg/g b.w.). Drugs were administered at intervals of more than 48 
hrs during the afternoon. All recordings and data analysis were done using a computerized
PM).  Measurements were taken during 10 mins of repeated 
measurement of tail cuff systolic blood pressure. Blood pressure was then calculated as mean of 
three days measurements after sufficient training of the animals. 
 data 
acquisition system and software (Power Lab 400 and Chart 
 
4; AdInstruments).  
9.2.3 Measurement of Serum Epinephrine and Norepinephrine  Concentrations  
To obtain blood specimens suitable for measurement of plasma catecholamines as described 
(Grouzmann E, et al., 2003), animals were lightly anesthetized with diethylether (Roth, Karlsruhe, 
Germany) or isoflurane (Essex, Munich, Germany) and about 200 μl of blood was withdrawn into 
heparinized capillaries by puncturing the retro-orbital plexus. Plasma epinephrine and 
norepinephrine concentrations were measured using an ELISA kit (Labor Diagnostika Nord, 
Nordhorn, Germany).  
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9.2.4 Measurement of urinary vanilylmandelic acid and epinephrine concentrations  
For evaluation of renal excretion, both, gsk3WT and gsk3KI
 
 mice were placed individually 
in metabolic cages (Techniplast, Hohenpeissenberg, Germany) for 24 h urine collection as 
described previously (Vallon V., 2003). For measurement of urinary epinephrine, urine was 
collected following a 12hr light or dark period. To adapt to the new environment, the animals 
were allowed a 3 day habituation period. Subsequently, a small amount of 6 M HCl was added to 
the urine collecting tube placed in the cage, and the acidic urine was collected for the next 24 
hours and urinary Vanilyl Mandelic Acid (VMA) concentrations were determined utilizing high 
pressure liquid chromatography (HPLC). Urine epinephrine concentrations were measured using 
an ELISA kit (Labor Diagnostika Nord, Nordhorn, Germany). To assure quantitative urine 
collection, metabolic cages were siliconized, and urine was collected under water-saturated oil.  
9.2.5 Adrenal gland histology 
 Adrenal glands of both, gsk3WT and gsk3KI mice were removed after sacrificing the 
animal. Tissues were immediately fixed by 4% formaldehyde overnight and embedded in 
paraffin. Tissues were cut in the mid-section of the adrenal gland and after mounting on glass 
slides stained with hematoxylin and eosin (Roth, 
 
Karlsruhe, Germany). Slides were digitized on a 
Zeiss Axio Observer.A1 microscope utilizing Zeiss Axiovision software (Zeiss AG, Oberkochen, 
Germany). Images were evaluated with Image J software (http://rsbweb.nih.gov/ij/). 
9.2.6 Immunofluorescence 
To show the expression of GSK3, 5-µm-thick frozen tissue sections from the adrenal 
glands of gsk3WT mice were fixed with 4% PFA for 15 min at room temperature. After washing 
twice with PBS the slides were incubated with 5% normal goat serum/1x PBS/0.3% Triton for 1 
hour at room temperature. Then, the specimens were exposed overnight at 4°C to GSK3 antibody 
(1:100, Cell Signaling, USA). The slides were rinsed three times with PBS and incubated for 1.5 
h at room temperature with secondary FITC goat anti-rabbit antibody (1:1000, Invitrogen, UK). 
After three washing steps the nuclei were stained for 10 min at room temperature with DRAQ-5 
dye (1:1000, Biostatus, Leicestershire, UK). All the slides and coverslips were mounted with 
ProLong Gold antifade reagent (Invitrogen, UK). Images were taken on a Zeiss LSM 5 
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EXCITER Confocal Laser Scanning Microscope (Carl Zeiss MicroImaging GmbH, Germany) 
with a water immersion Plan-Neofluar 40_/1.3 NA DIC. Images were analyzed with the 
instrument's software. 
 
9.2.7 In Vitro Expression 
For generation of cRNA, constructs were used encoding wild-type human NaPi-IIa 
(Busch AE, et al., 1995) and human GSK3β. The cRNA was generated as described previously 
(Strutz-Seebohm N, et al., 2007). GSK3β cDNA was from the “Deutsches Ressourcenzentrum 
fu¨r Genomforschung,” Berlin, Germany. For electrophysiology, Xenopus oocytes were prepared 
as described previously (Boehmer C, et al., 2008 and Boehmer C, et al., 2008). Ten nanograms 
of NaPi-IIa cRNA was injected on the first day and 7.5 ng of GSK3β cRNA was injected on the 
second day after preparation of Xenopus oocytes. All experiments were performed at room 
temperature 3 days after the second injection. Two electrode voltage-clamp recordings were 
performed at a holding potential of -50 mV. The data were filtered at 10 Hz and recorded with a 
Digidata A/D-D/A converter and Chart V.4.2 software for data acquisition and analysis (Axon 
Instruments). The control solution (superfusate/ND96) contained 96 mM NaCl, 2 mM KCl, 1.8 
mM CaCl2, 1 mM MgCl2, and 5 mM HEPES, pH 7.4. Phosphate (2 mM) was added to induce 
NaPi-IIa– dependent currents. The flow rate of the superfusion was 20 ml/min, and a complete 
exchange of the bath solution was reached within about 10 seconds. For the determination of 
NaPi-IIa surface expression, defolliculated oocytes were incubated with primary rabbit anti-
NaPi-IIa antibody (diluted 1:500; Lifespan Biosciences, Seattle, WA) and secondary, 
peroxidase-conjugated goat antirabbit antibody (diluted 1:1000; Cell Signaling, Danvers, MA). 
Individual oocytes were placed in 96-well plates with 10 µl of Super Signal ELISA Femto 
Maximum Sensitivity Substrate (Pierce, Rockford, IL). The chemiluminescence of the oocytes 
was quantified in a luminometer (WalterWallac2 plate reader; Perkin Elmer, Jǜ gesheim, 
Germany) by integrating the signal over a period of 1 second. Results display normalized 
arbitrary light units that are proportional to the detector voltage. 
 
9.2.8 In Vivo Urine collection  Experiments and dietary treatment 
The mice were compared with corresponding wild-type mice (gsk3WT). The mice were 
fed control diet (Altromin, Lage, Germany) containing 7523 mg/kg phosphorus or a phosphorus-
Materials and methods 
 
44 
 
deficient diet containing 131 mg/kg phosphorus, as indicated. They had free access to tap 
drinking water. To determine creatinine clearance, urinary flow rate, and urinary excretion of 
Ca2+ and phosphate, the mice were placed individually in metabolic cages (Techniplast, 
Hohenpeissenberg, Germany) for 24-hour urine collection as described previously (Vallon V,  
2003). They were allowed a 2-day habituation period, during which food and water intake, 
urinary flow rate, and excretion of electrolytes were recorded every day to ascertain that the mice 
were adapted to the new environment. Subsequently, 24-hour collection of urine was performed 
for 3 consecutive days to obtain the urinary parameters. To assure quantitative urine collection, 
metabolic cages were siliconized, and urine was collected under water-saturated oil. The 
phosphate concentration was determined colorimetrically using commercial diagnostic kits 
(Roche Diagnostics, Mannheim, Germany). The urinary concentration of Ca2+
Bone density analysis 
 was measured by 
flame photometry (ELEX 6361; Eppendorf) or by a photometric method according to the 
manufacturer’s instructions (dri-chem clinical chemistry analyzer FUJI FDC 3500i; Sysmex, 
Norsted, Germany). The creatinine concentration in urine was determined using the Jaffe 
reaction (Sigma, St. Louis, MO); creatinine and calcium concentration in plasma were measured 
using a photometric method. The plasma intact parathormone concentration was measured using 
an ELISA kit (Immunotopics, San Clemante, CA). A radioimmunassay kit was used to determine 
the concentration of 1,25-(OH)2D3 (IDS, Boldon, UK) in plasma.  
For the analysis of bone density, animals were killed, and legs were amputated and fixated in 
formalin. The samples were scanned with a high-resolution microCAT-II (Siemens Preclinical 
Solutions) small animal computed tomography (CT) scanner using a field of view of 3.1×3.1×4.8 
cm3. The x-ray tube parameters were set at 80 kVp and 400 µA. The images were acquired with 
720 angular projections (exposure time, 1200 ms per projection) over 360° and binned with a 
factor of two, yielding a spatial resolution of approximately 38 µm. The total scan time was 24 
minutes. Reconstructed CT images were analyzed with the Inveon Research Workplace software 
(Siemens Preclinical Solutions) by drawing a standard-sized container around the femur and 
applying a region growth routine to segment the trabecular bone structure. For all samples, the 
same upper and lower density threshold was applied, and the relative numbers of trabecular bone 
density were compared. 
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Blood and urinary concentrations 
To obtain blood specimens, animals were lightly anesthetized with diethyl ether (Roth, 
Karlsruhe, Germany) and approximately 150 μl of blood was withdrawn into heparinized 
capillaries by puncturing the retro-orbital plexus. Plasma and urinary concentrations of Na+, K+ 
and Ca2+ were measured by flame photometry (AFM 5051, Eppendorf, Germany). Plasma and 
urinary creatinine concentrations were measured by using an enzymatic colorimetric method 
(Creatinine PAP, Labortechnik, Berlin, Germany).  
 
9.2.9 RNA Extraction and Real-Time RT-PCR 
Snap-frozen kidneys were homogenized in RLT-Buffer (Qiagen, Basel, Switzerland) and 
supplemented with ß-mercaptoethanol, resulting in a final concentration of 1%. Total RNA was 
extracted and reverse transcribed as described previously (Nowik M, et al., 2008). Quantitative 
real-time qRT-PCR was performed on the ABI PRISM 7700 Sequence Detection System 
(Applied Biosystems). Primers for all genes of interest were as described (Nowik M, et al., 
2008). For analysis of the data, the threshold was set to 0.06 because this value had been 
determined to be in the linear range of the amplification curves for all mRNAs in all 
experimental runs. The expression of the gene of interest was calculated in relation to 
hypoxanthine guanine phosphoribosyl transferase. Relative expression ratios were calculated 
asR=2[Ct(HPRT)_Ct(test gene)]
 
, where Ct represents the cycle number at the threshold 0.06. 
9.2.10 BBMV Preparation and Phosphate Transport Assays 
BBMVs were prepared from rat kidney cortex and outer medulla using the Mg2+ precipitation 
technique as described previously (Biber J, et al., 1981 and Biber J, et al., 2007). The phosphate 
transport rate into BBMVs was measured in freshly prepared BBMVs at 25°C in the presence of 
inward gradients of 100mM NaCl or 100mM KCl and 0.1mM K-phosphate. The substrate Pi was 
prepared with 0.125 mM K2HPO4 and (Brown AJ, et al., 2002) P (1 µCi/ml) to yield a final 
concentration of 0.1 mM, close to the expected apparent KmPi for Na+ -dependent transport in 
renal BBMVs. The stop solution contained 100mM mannitol, 5mM Tris-HCl, pH7.4, 150mM 
NaCl, and 5mM Pi. The Na+ dependence was established by incubating BBMVs in solutions in 
which KCl replaced NaCl equimolarly. Phosphate uptake was determined after 60 seconds, 
representing initial linear conditions, and after 120 minutes, to determine the equilibrium values. 
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To distinguish between Na+ -dependent Pi uptake mediated by SLC34 family members (e.g., 
NaPi-IIa and NaPi-IIc) and other Na+ 
 
-dependent phosphate transporters such as SLC20 family 
members (e.g., Pit-1 and Pit-2), we used trisodium PFA (final concentration, 6 mM) added to the 
same solution with 107 mM NaCl. PFA has previously been shown to have a higher selectivity 
for SLC34 than for SLC20 phosphate transporters at this concentration (Villa-Bellosta R, et al., 
2009). The total protein concentration was measured using the Bio-Rad Protein Assay kit (Bio-
Rad, Hercules, CA). BBMVs were stored at ─80°C until further use. 
9.2.11 Western Blotting 
After measurement of the protein concentration (Bio-Rad), 10 µg of renal brush border 
membrane proteins was solubilized in loading buffer containing dithiothreitol and separated on 
8% polyacrylamide gels. For immunoblotting, the proteins were transferred electrophoretically to 
polyvinylidene fluoride membranes (Immobilon-P; Millipore, Bedford, MA). After blocking 
with 5% milk powder in Trisbuffered saline/0.1% Tween-20 for 60 minutes, the blots were 
incubated with the primary antibodies: rabbit polyclonal anti-NaPi-IIa (1:6000),45 rabbit 
polyclonal anti-NaPi-IIc (1:10,000), (Nowik M, et al., 2009) rabbit polyclonal anti-Pit-2 (1:3000; 
kindly provided by Dr. V. Sorribas, University of Zaragoza, Spain) (Villa-Bellosta R, et al., 
2009), and mouse monoclonal anti-β-actin antibody (42 kD; Sigma; 1:5000) either for 2 hours at 
room temperature or overnight at 4°C. Membranes were incubated for 1 hour at room 
temperature with secondary goat anti-rabbit or donkey anti-mouse antibodies 1:5000 linked to 
alkaline phosphatase (Promega) or to horseradish peroxidase (Amersham). The protein signal 
was detected with the appropriate substrates (Millipore) using the DIANA III-
chemiluminescence detection system (Raytest, Straubenhardt, Germany). All images were 
analyzed using the software Advanced Image Data Analyzer AIDA, Raytest to calculate the 
protein of interest/β-actin ratio. 
 
9.2.12 Statistical Analysis 
Data are provided as means ± SEM; n represents the number of independent experiments. All 
data were tested for significance using paired or unpaired t tests or ANOVA. GraphPad InStat 
version 3.00 for Windows 95 (GraphPad Software, San Diego, CA) was used. Only results with 
P < 0.05 were considered statistically significant. 
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10. RESULTS 
10.1 GSK3 and Catecholamine 
 Similar to what was reported earlier (Boini KM, et al., 2008), the blood pressure was 
significantly (p<0.01) higher in gsk3KI mice (112 ± 3 mmHg, n = 6) than in gsk3WT mice (96 ± 4 
mmHg, n = 7; mean of 3 days measurement after 7 days training). Moreover, heart rate was 
significantly (p<0.001) higher in gsk3KI mice (575 ± 15 bpm, n = 6) than in gsk3WT mice (431 ± 13 
bpm, n = 7). To explore whether the hypertension of gsk3KI resulted from increased adrenergic 
stimulation, the effect of adrenergic receptor blockers on blood pressure of gsk3KI and gsk3WT mice 
was analysed. As a result, treatment with the α-adrenergic blocker prazosine (1 µg/g b.w.)  resulted 
in a decrease of blood pressure to a larger extent in gsk3KI than in gsk3WT  mice (Fig. 10.1.1). In the 
presence of prazosine, the blood pressure still tended to be slightly higher in gsk3KI mice (95 ± 5 
mmHg, n = 6) than in gsk3WT mice (89 ± 4 mmHg, n = 7), a difference, however, not reaching 
statistical significance. Treatment with the ganglion blocker hexamethonium (40 µg/g b.w.) was 
followed by a more profound decrease of blood pressure in gsk3KI mice (Fig. 10.1.1). In the 
presence of hexamethonium blood pressure was identical in gsk3KI mice (81± 5 mmHg, n = 6) and 
in gsk3WT
 Additionaly, blood pressure was again determined in another study group of anaesthetized 
mice (1.5% isoflurane). Under isoflurane anesthesia, gsk3
 mice (81 ± 6 mmHg, n = 7).   
KI mice showed a similar tendency for 
increased blood pressure (119 ± 5mmHg in gsk3KI mice vs 101 ± mmHg in gsk3WT mice, p<0.01; 
Fig. 10.1.2). Treatment with prazosin did produce a more pronounced decrease in blood pressure in 
gsk3KI mice, which abrogated the differences in blood pressure between gsk3KI mice (86 ± 2 
mmHg, n = 6) and gsk3WT mice (88 ± 1 mmHg n = 6). After similar baseline blood pressure 
measurements (gsk3KI 126 ± 1 mmHg, gsk3WT 107 ± 3 mmHg; p<0.01), treatment with the ganglion 
blocker hexamethonium (40 µg/g b.w.) again reduced blood pressure of gsk3KI mice (96 ± 1 
mmHg, n = 5) to similar levels as in gsk3WT
 Treatment of gsk3
 mice (97 ± 5 mmHg, n = 6; Fig. 10.2.2).   
KI and gsk3WT mice with the ß-blocker atenolol (5 µg/g b.w.) did not 
significantly decrease blood pressure, but significantly decreased heart rate (Fig. 10.1.3) in mice 
anaesthetized with 1.5% isoflurane. Atenolol decreased heart rate significantly more in gsk3KI mice 
than in gsk3WT mice. As a result, in the presence of atenolol the heart rate was not significantly 
different between gsk3KI mice (371 ± 23 bpm, n = 6) and gsk3WT mice (353± 21 bpm, n = 7). 
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 The increased blood pressure could result from stimulation of sympathetic activity with 
enhanced catecholamine release. As illustrated in Fig.10.1.4A, the plasma epinephrine 
concentration was indeed significantly (p<0.0001) higher in gsk3KI mice than in gsk3WT mice. A 
similar difference could be observed while using a different anaesthetic regimen during the 
collection of the blood, namely isoflurane anaesthesia (Fig 10.1.4B). Concordantely, the 
norepinephrine plasma concentration was significantly (p<0.01) higher in gsk3KI mice than in 
gsk3WT
 The increased plasma catecholamine concentrations could have resulted from enhanced 
release or delayed degradation of catecholamines. To discriminate between those two possibilities, 
the urinary excretion of epinephrine and the catecholamine degradation product vanilyl mandelic 
acid was determined. As shown in Fig. 10.1.5A, the urinary excretion of vanilyl mandelic acid 
was significantly (p<0.05) higher in gsk3
 mice (Fig. 10.1.4C).  
KI than in gsk3WT mice.  Urinary epinephrine levels were 
increased in gsk3KI
 In theory, the increased production of catecholamines in gsk3
 mice during a 12hr dark (Fig. 10.1.5B) as well asa 12 hr light period (5C, both 
p<0.01). 
KI mice could have been 
dependent on a pheochromocytoma or hypertrophy of the adrenal medulla. No abnormalities could 
be shown by histological evaluation of the adrenal gland (Fig 10.1.6). Furthermore, adrenal medulla 
size was not significantly different between gsk3KI mice (161 ± 22 mm², n = 7) and gsk3WT
 If gsk3 is involved in the production or release of catecholamines, it should be  expressed in 
chromaffine cells of the adrenal medulla. As shown by immunostaining in Fig. 10.1.7, gsk3 is 
expression could be detected by confocal microscopy after immunostaining in the adrenal glands of 
gsk3
 mice 
(155 ± 23 mm², n=6).  
WT
 
 mice.  
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Fig. 10.1.1: Systolic blood pressure in gsk3KI and gsk3WT
Arithmetic means ± SEM of systolic blood pressure (mmHg) in GSK3 knockin mice (gsk3
 mice prior to and following 
administration of prazosine or hexamethonium in conscious mice   
KI, 
closed bars; n=6) and wild type mice (gsk3WT, open bars; n=7) at baseline (mean of three days 
measurement) and after administration of prazosin (1 µg/g b.w.) and hexamethonium chloride (40 
µg/g b.w.); treatments performed on different non-consecutive days. ANOVA, ** indicates 
significant (p<0.01) difference from respective value of gsk3WT
 
 mice. 
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Fig. 10.1.2: Systolic blood pressure in gsk3KI and gsk3WT
a. Arithmetic means ± SEM of systolic blood pressure (mmHg) in GSK3 knockin mice (gsk3
 mice prior to and following 
administration of prazosine or hexamethonium under isoflurane anaesthesia 
KI, 
closed bars; n=5-6) and wild type mice (gsk3WT, open bars; n=6). Measurements were performed 
under 1.5% isoflurane anaesthesia at baseline and immediatley followed by administration of 
prazosin (1 µg/g b.w.). b. Arithmetic means ± SEM of systolic blood pressure (millimeters of 
mercury) in GSK3 knockin mice (gsk3KI, closed bars; n=5) and wild type mice (gsk3WT, open 
bars; n=6). Measurements were performed under 1.5% isoflurane anesthesia at baseline and 
immediately followed by administration of prazosin and hexamethonium chloride (40 µg/g b.w.). 
ANOVA; ** and *** indicates significant (p<0.01, p<0.001) difference from respective value of 
gsk3WT
 
 mice; ## and ### indicates significant (p<0.01, p<0.001) difference from respective baseline 
value of the same genotype.   
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Fig.10.1.3: Systolic blood pressure and heart rate in gsk3KI and gsk3WT
A. Arithmetic means ± SEM of systolic blood pressure (mmHg) in GSK3 knockin mice (gsk3
 mice prior to and 
following administration of atenolol under isoflurane anaesthesia 
KI, 
closed bars; n = 6) and wild type mice (gsk3WT, open bars; n = 6) before and after atenolol 
treatment (5µg/g). ANOVA, *,** and *** indicates significant (p<0.05, p<0.01, p<0.001) 
difference from respective value of gsk3WT
B. Arithmetic means ± SEM of heart rate (beats/min) in GSK3 knockin mice (gsk3
 mice. 
KI, closed bars; 
n = 6) and wild type mice (gsk3WT, open bars; n = 7) before and after atenolol treatment (5 µg/g). 
ANOVA, *** indicates significant (p<0.001) difference from respective value of gsk3WT
 
 mice; #, 
### indicates significant (p<0.05, p<0.001) difference from respective baseline value of the same 
genotype.  . 
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Fig. 10.1.4: Plasma epinephrine and norepinephrine concentrations in gsk3KI and gsk3WT
Arithmetic means ± SEM of plasma epinephrine under ether (A) or isoflurane anaesthesia (b) 
and norepinephrine (C) concentrations in GSK3 knockin mice (gsk3
 
mice  
KI, closed bars; n = 6) and 
wild type mice (gsk3WT, open bars; n = 8). T-test,  **, *** indicate significant (p<0.01, p<0.001) 
difference from respective value of gsk3WT
 
 mice. 
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Fig. 10.1.5: Urinary vanilylmandelic acid and epinephrine concentrations in gsk3KI and 
gsk3WT
Arithmetic means ± SEM of urinary vanilylmandelic acid concentration (A) and epinephrine 
concentrations during 12hr dark (B) or light (C) period in GSK3 knockin mice (gsk3
 mice  
KI, closed 
bars; n = 6) and wild type mice (gsk3WT, open bars; n = 6). T-Test, *,** indicates significant 
(p<0.05, p<0.01) difference from respective value of gsk3WT
 
 mice. 
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Fig. 10.1.6: Histological sections of adrenal glands of gsk3KI and gsk3WT
A. Arithmetic means ± SEM of midsectional area (mm²) of the adrenal medulla in GSK3 knockin 
mice (gsk3
 mice 
KI, closed bars; n = 6) and wild type mice (gsk3WT
B. Example images of adrenal glands from GSK3 knockin mice (gsk3
, open bars; n = 6).  
KI) and wild type mice 
(gsk3WT
 
). Scale bar indicates 100 μm 
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Fig. 10.1.7: GSK3 Expression in adrenal glands of gsk3WT
Confocal laser scanning microscopic analysis of adrenal glands of gsk3
 mice 
WT mice frozen sections 
stained with anti-GSK3 antibody, and anti-rabbit-FITC was used as secondary antibody. Pictures 
show specific FITC-related fluorescence at adrenal glands of gsk3WT
 
 mice (a). Nuclei were 
visualized by DRAQ5™ staining and merged (b).  
 
 
 
 
 
A 
B 
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10.2  GSK3, Phosphaturia and Calciuria 
The reabsorption of phosphate (Pi) from the proximal tubule is mainly determined by 
sodium-dependent transports expressed in the brush border membrane. Electrophysiological 
studies reveal that Pi transport via Na/pi cotransporters is electrogenic (Murer H and Biber J., 
1996). Hence in the first series of our study, we analyzed the influence of GSK3β on Napi-IIa, a 
major renal tubular sodium-dependent phosphate transporter in vitro. We found that Xenopus 
oocytes injected with water, upon exposure to phosphate (2mM) in  bath solution did not induce 
any significant current, confirming that these oocytes do not express any significant endogenous 
electrogenic phosphate transporter (Figure 10.2.1A). In the same set of experiment oocytes 
injected with cRNA encoding electrogenic phosphate transporter NaPi-IIa, and upon exposure to 
phosphate as previous, showed an inward current  of 58 ± 10 nA (n=21 oocytes). Whereas 
coexpression of GSK3β with phosphate transporter NaPi-IIa in the Xenopus oocytes showed 
decreased an inward current of 27 ± 5 nA (n = 17 oocytes). To determine the in vitro influence of 
GSK3β on the membrane abundance of Napi-IIa, a chemiluminescence-based assay was 
performed. To this end we found significant reduction in surface expression of NaPi-IIa by 
coexpression of GSK3β (Figure 10.2.1B). The decrease of NaPiIIa activity is not simply caused 
by the expression of an additional protein. The phosphate induced current in NaPi-Iia– 
expressing oocytes is, for instance, similar with and without coexpression of mTOR, when the 
kinase is inhibited by rapamycin (Kempe DS, et al., 2010).  
To explore further, the activity and expression of sodium-dependent electrogenic 
phosphate transporters of both family SLC34 (e.g., NaPi-IIa and NaPi-IIc) and SLC20 (e.g., Pit-
1 and Pit-2), in brush border membrane vesicles (BBMVs) from the kidney cortex and outer 
medulla of GSK3αβ knockin (ki) mice (gsk3KI) and corresponding wild-type (wt) mice (gsk3WT) 
was assessed. Both SLC34A1 and SLC34A3 are localized at the brush border membrane of 
proximal tubule cells and have not been detected in other segments of the nephron (Custer M, et 
al., 1994 and Segawa H., et al., 2002). In the absences of phosphonoformic acid (PFA, 6 mM) 
the sodium-dependent uptake of phosphate by both families of phosphate transporters (NaPi-IIa, 
NaPi-IIc, Pit-1 and Pit-2) into BBMVs was significantly reduced in gsk3KI mice (Figure 10.2.2).  
In presence of phosphonoformic acid (PFA, 6 mM), the sodium-dependent uptake of phosphate 
by SLC20 families (e.g., Pit-1 and Pit-2) of phosphate transporters into BBMVs was 
significantly reduced in both genotypes (Figure 10.2.2). Upon addition of phosphonoformic acid 
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(PFA, 6 mM) gsk3KI mice still shows less residual sodium-dependent phosphate transport activity 
compared to corresponding wild-type (wt) mice (gsk3WT
In order to investigate the abundance of phosphate transporters (NaPi-IIa, NaPi-IIc, and 
Pit-2), additional experiment of immunoblotting of kidney cortex of BBMVs was performed. As 
shown in Figure 10.2.3, significantly reduced abundance of NaPi-IIa and of NaPi-IIc protein was 
found in gsk3
).  
KI mice compared with corresponding wild-type (wt) mice (gsk3WT). 
Semiquantitative real-time PCR analysis showed significantly increased mRNA abundance of 
NaPi-IIa and Pit-2 in gsk3KI mice, suggesting that GSK3 acts partially upstream of the 
transcription of these transporters (all data expressed as mRNA expression normalized to HPRT 
mRNA abundance; see Concise Methods; NaPi-IIa: gsk3WT: 29.0 ± 3.2, n = 6; gsk3KI: 59.97 ± 
11.12, n = 5; P < 0.05; NaPi-IIc: gsk3WT: 0.22 ± 0.01, n = 6; gsk3KI: 0.22 ± 0.03, n = 5; not 
significant; Pit-2: gsk3WT: 0.16 ± 0.01, n = 6; gsk3KI
Similar to what was reported earlier (Boini KM, et al., 2008), in vivo metabolic cage 
experiments were performed in gsk3
: 0.34 ± 0.04, n = 5; P < 0.01).  
KI and gsk3WT mice. The body weight was found similar in 
both gsk3KI mice (29.1 ± 0.3 g, n = 10) and gsk3WT mice (28.9 ± 1.4 g, n = 10).  The urinary flow 
rate was significantly higher in gsk3KI mice (95.2 ± 10.1µl/24 h per gram body weight, n = 6) 
compared with corresponding wild-type mice (gsk3WT) (24.1 ± 4.8µl/24 h per gram body weight, 
n = 6). Additionally the creatinine clearance was significantly higher in gsk3KI mice (0.39 ± 0.06 
ml/24 h, n = 6) than in gsk3WT
To determine renal handling of phosphate in both gsk3
 mice (0.19 ± 0.02 ml/24 h, n = 6).  
KI and gsk3WT mice fed on control 
diet and phosphorus-deficient diet, we perform metabolic cages experiments and determined 
urinary phosphate excretion and the fractional phosphate excretion. As shown in Figure 10.2.4 
(top right panel), under normal diet the urinary phosphate excretion was significantly larger in 
gsk3KI than corresponding wild-type mice (gsk3WT). The fractional phosphate excretion before 
starting phosphorus-deficient diet was found higher in gsk3KI (63.9 ± 13.6%) (n=6) than 
corresponding wild-type mice (gsk3WT) 31.1 ± 6.9% (n = 5). The values were not significantly 
different. But on the 3rd day after phosphorus-deficient diet, the fractional phosphate excretion 
amounted to 1.4 ± 0.1% (n = 5) in gsk3WT mice and to 31.8 ± 11.1% (n = 6) in gsk3KI mice, 
values significantly (P < 0.05) different (Figure 10.2.4, bottom panel).  Theoretically 
hyperphosphatemia (abnormally elevated level of phosphatein in blood) expected to cause excess 
excretion of urinary phosphate. However, gsk3KI mice showed significantly lower plasma 
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phosphate concentration compared to corresponding wild-type mice (gsk3WT), as shown in Figure 
10.2.4, top left panel. This could be due to decreased intestinal uptake of phosphate because 
plasma PTH and activated vitamin D (1,25-(OH)2D3) control its uptake (Brown AJ, et al., 
2002). As our gsk3KI 
To explore further reason of phosphaturia, as renal tubular reabsorption of phosphate is 
controlled by plasma PTH and 1,25-(OH)2 vitamin D3 (Murer H, et al., 2000), we determined 
plasma PTH and 1,25-(OH)2 vitamin D3 in both gsk3
mice has lower plasma concentrations of PTH and activated vitamin D 
(1,25-(OH)2D3), naturally the uptake of phosphate in the intestine is less and hence plasma 
concentration is less. 
KI and wild-type mice (gsk3WT). However, 
as shown in Figure 10.2.5A (left panel), the plasma concentration of PTH was significantly 
lower in gsk3KI than in corresponding wild-type mice (gsk3WT). The plasma PTH stimulates the 
renal 1α-hydroxylase (Portale AA, et al., 2000), the rate-limiting enzyme of 1,25-(OH)2D3 
formation (Portale AA, et al., 2000 and Kato S, 1999). So low plasma PTH levels are expected to 
decrease the plasma 1,25-(OH)2 D3 concentration. As shown in Figure 10.2.5A (right panel), the 
plasma concentration of 1,25- (OH)2 D3 was indeed significantly lower in gsk3KI than in 
corresponding wild-type mice (gsk3WT). As 25-hydroxyvitamin D3 1α-hydroxylase catalyzes the 
last step in the synthesis of the active 1,25-(OH)2D3, we determined mRNA expression of 
CYP27B1 (25-hydroxyvitamin D3 1a-hydroxylase) in both gsk3KI and wild-type mice (gsk3WT). 
We found higher transcript levels of CYP27B1 (25-hydroxyvitamin D3 1α-hydroxylase) in 
gsk3KI mice than in corresponding wild-type mice (gsk3WT
As the PTH stimulates the absorption of calcium across the intestinal brush border 
membrane, passing through ion channels such as TRPV6 (is a member of Transient receptor 
potential selective for calcium ions) (
); this difference, however, did not 
reach statistical significance (Figure 10.2.5B).  
Barley NF et al., 2001). Expression of TRPV6 is 1,25-
(OH)2 D3 dependent. Indeed our gsk3KI mice has lower plasma Ca2+ concentration compared 
with corresponding wild-type mice (gsk3WT); this difference, however, did not reach statistical 
significance (Figure 10.2.6, left panel).   The plasma PTH and 1,25-(OH)2 vitamin D3 stimulates 
renal tubular reabsorption of Ca2+ + via upregulation of the TRPV5 channels. Hence decreased 
plasma PTH and 1,25-(OH)2 vitamin D3 concentration is expected to blunt the renal tubular 
Ca2+ reabsorption. As shown in Figure 10.2.6 (right panel), the renal Ca2+ excretion were indeed 
larger in gsk3KI than in gsk3WT mice. Additional experiments in  metabolic cages with normal 
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diet and a phosphorus-deficient diet for 3 days were performed and fractional excretion of 
calcium was determined. We found significantly higher values of fractional excretions of 
calcium in gsk3KI mice fed on normal diet (2.4 ± 0.2%, n = 5) compared with corresponding 
wild-type mice (gsk3WT) (1.6 ± 0.2%, n = 4).. On 3rd day after starting phosphorus-deficient diet,  
fractional excretion of calcium were found to be 0.8 ± 0.1% (n = 4) in gsk3WT mice and that of 
11.7 ± 5.4% (n = 5) in gsk3KI
The bone mineralization controlled at three level, systemic hormones, bone cells 
(osteoblasts, osteoclasts and osoteocyts) and cell products, acting in a paracrine / autocrine 
manner. The mineral ions Ca
 mice. 
2+ and Pi along with PTH and 1,25-(OH)2 vitamin D3 play a central 
role in controlling bone mineralization (Roney S. and Gregory L., 2011). Our gsk3KI mice 
shows excess renal loss of both Ca2+  and phosphate together with low PTH and 1,25-(OH)2 
vitamin D3 levels is expected to compromise the mineralization of bone. Thus, bone density was 
determined. As shown in Figure 10.2.7, femur bone density was indeed significantly lower in 
gsk3KI than in gsk3WT
 
 mice. 
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Fig.10.2.1. Coexpression of GSK3 inhibits electrogenic phosphate transport in NaPi-IIa– 
expressing Xenopus oocytes.  
(A) Arithmetic means ± SEM (n = 13 to 21) of phosphate (2 mM)-induced inward currents (IPi
 
) 
in Xenopus oocytes injected with water (left bar), Napi-IIa cRNA (middle bar), or Napi-IIa and 
GSK3β cRNA (right bar). ***Statistically significant difference from absence of Napi- IIa 
cRNA (P < 0.001). #Difference from absence of GSK3β cRNA (P < 0.05). (B) Arithmetic means 
± SEM (n = 42 to 60) of the normalized chemiluminescence intensity of Napi-IIa expression in 
Xenopus oocytes injected with water (left bar), Napi-IIa cRNA (middle bar), or Napi-IIa and 
GSK3β cRNA (right bar). ***Statistically significant difference from absence of Napi-IIa cRNA 
(P < 0.001). ###Difference from absence of GSK3β cRNA (P < 0.001).  
 
 
 
 
 
 
 
 
 
 
Results 
 
61 
 
 
 
 
 
 
 
 
 
Fig.10.2.2. Sodium-dependent phosphate transport activity in BBMVs from gsk3KI and 
gsk3WT
Arithmetic means ± SEM (n = 5 to 6 each group) of the sodium-dependent transport rates into 
isolated BBMVs after 1 minute in the absence (left bars) and presence (right bars) of 6 mM PFA 
to block phosphate transport mediated by SLC34 family members. *P < 0.05. 
 mice.  
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Fig.10.2.3. Protein abundance of renal sodium-dependent phosphate cotransporters in the 
brush border membrane in KIdneys from gsk3KI and gsk3WT
Western blots for NaPi-IIa, NaPi-IIc, and Pit-2. All membranes were stripped and reprobed for 
β-actin to control for loading. Densitometry was performed and the ratio of the protein of interest 
over β-actin calculated. Bar graphs present data as arithmetic means ± SEM (n = 5 to 6 each 
group). 
 mice.  
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Fig.10.2.4. Plasma phosphate concentration, urinary phosphate excretion, and fractional 
phosphate excretion in gsk3KI and gsk3WT
Arithmetic means ± SEM (n = 6 to 10) of plasma phosphate concentration (top left panel) and 
urinary phosphate excretion (top right panel) in GSK3 knockin mice (gsk3
 mice.  
KI, closed bars) and 
corresponding wild-type mice (gsk3WT, open bars). The bottom panel depicts the arithmetic 
means ± SEM (n = 5 to 6) of the fractional phosphate excretion of GSK3 knockin mice and wild 
type mice maintained under a normal diet (left bars) or maintained for 3 days under a 
phosphorus-deficient diet (right bars). *P < 0.05 versus respective value of gsk3WT
 
 mice 
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Fig.10.2.5. Plasma PTH and 1,25-(OH)2D3 concentration in gsk3KI and gsk3WT
(A) Arithmetic means ± SEM of plasma PTH (left panel, n = 6) and 1,25-(OH)2D3 (right panel, 
n = 17 to 19) concentration in GSK3 knockin mice (gsk3
 mice.  
KI, closed bars) and corresponding wild-
type mice (gsk3WT, open bars). *P < 0.05 versus respective value of gsk3WT
 
 mice. (B) mRNA 
expression of CYP27B1 (25-hydroxyvitamin D3 1a-hydroxylase). Arithmetic means ± SEM (n = 
5 to 6). 
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Fig.10.2.6. Plasma calcium concentration and urinary calcium excretion in gsk3KI and 
gsk3WT
Arithmetic means ± SEM (n = 6 to 19) of plasma calcium concentration (left panel) and urinary 
calcium excretion (right panel) in GSK3 knockin mice (gsk3
 mice.  
KI, closed bars) and corresponding 
wild-type mice (gsk3WT, open bars). *P < 0.05 versus respective value of gsk3WT
 
 mice. 
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Fig.10.2.7. Bone density of gsk3KI and gsk3WT
(A) Arithmetic means ± SEM (n = 4 each group) of bone density in GSK3 knockin mice (gsk3
 mice.  
KI, 
closed bar) and corresponding wild-type mice (gsk3WT, open bar). *P < 0.05 versus respective 
value of gsk3WT mice. (B) Original microCT image of the leg of a GSK3 knockin mice (gsk3KI, 
right image) and of a corresponding wildtype mouse (gsk3WT, left image). (C) Cuts from 
microCT images in tranaxial, coronal, and sagittal directions through the femur and knee. These 
high-resolution microCT images display the degradation of trabecular bone and compacta in 
GSK3 knockin mice (gsk3KI, right image) and in wild-type mice (gsk3WT, left image). 
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11. DISCUSSION & CONCLUSION 
The primary aim of the current study was to determine the role of protein kinase 
B(PKB)/Serum and glucocorticoid inducible kinase (SGK) resistant glycogen synthase GSK3 in the 
handling of catecholamine release, renal calcium and phosphate excretion, and intestinal phosphate 
transport. 
In doing so, as the generations of GSK3β knockout mouse was not possible due to their 
embryonic death. we generated mice carrying a mutation of GSK-3α in which the codon 
encoding Ser21 was changed to encode a nonphosphorylatable Ala residue (GSK-3α 21A/21A), and 
at the same time carrying a mutation of GSK-3β in which the codon encoding Ser9 was changed 
to encode a nonphosphorylatable Ala residue (GSK-3β 9A/9A), are expected to be resistant to 
PKB/SGK-dependent phosphorylation of GSK-3. PI3 kinase-dependent inhibition of GSK3 
mediates the effect of insulin on glycogen synthase (Cohen P, et al., 2004 and McManus EJ, et 
al., 2005). Accordingly, the effect of insulin on muscle glycogen synthase is abrogated in gsk3KI
According to the present observations, mice carrying the PKB/SGK-resistant GSK-3 mutants 
(gsk3
 
mice (McManus EJ, et al., 2005). 
KI) shows significantly higher blood pressure and heart rate compared to their 
corresponding wild-type mice (gsk3WT). In addition to this our laboratory found increased urine 
flow in the (gsk3KI) mice corresponding to their wild-type mice (gsk3WT). With the further 
estimations of electrolytes from urine we come to known that, (gsk3KI
 
) mice has increased renal 
calcium and phosphate excretions. Further the results corresponding to above two aims have 
been discussed in detail. 
GSK3 and Catecholamine 
The present study discloses a novel function of phosphoinositide (PI) 3 kinase-dependent GSK3 
regulation, i.e. the tuning of catecholamine release. As observed earlier (Boini KM, et al., 2008), 
the arterial blood pressure is enhanced in mice expressing protein kinase B(PKB)/Serum and 
glucocorticoid inducible kinase (SGK) resistant glycogen synthase GSK3. The GSK3 isoforms were 
made resistant to PKB/SGK by introducing a mutation of GSK3ß, in which the serine of the PKB 
phosphorylation site had been replaced by an alanine (GSK3ß9A/9A) and a mutation in GSK3α, in 
which the serine of the PKB phosphorylation site had been replaced by an alanine 
(GSK3α12A/12A). PI3 kinase-dependent inhibition of GSK3 mediates the effect of insulin on 
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glycogen synthase (Cohen P, et al., 2004 and McManus EJ, et al., 2005). Accordingly, the effect 
of insulin on muscle glycogen synthase is abrogated in gsk3KI
 In the present study, we demonstrate that the increase in blood pressure is paralleled by 
an increase in heart rate under slight anaesthesia. The alterations of both parameters result from 
differences in catecholamine release, which was significantly higher in gsk3
 mice (McManus EJ, et al., 2005).  
KI mice than in 
gsk3WT
Accordingly, administration of the α-adrenergic receptor antagonist prazosine or the 
ganglion blocker hexamethonium decresased the blood pressure to a larger extent in gsk3
 mice.  
KI mice 
than in gsk3WT mice and virtually abolished the differences in blood pressure between gsk3KI and 
gsk3WT mice. Similar to what has been reported previously for several mouse strains 
(Berthonneche C, et al., 2009), administration of the β-adrenergic antagonist atenolol failed to 
significantly modify blood pressure in gsk3KI and gsk3WT mice. However, atenolol treatment 
virtually abrogated the differences of heart rate between gsk3KI and gsk3WT
The disappearance of the differences in heart rate following atenolol treatment indicates 
that the differences were not due to a direct regulation of intrinsic cardiac pacemaking activity by 
GSK3. Isolated hearts of gsk3
 mice.  
KI mice show a similar heart rate as gsk3WT mice (Webb IG, et al., 
2010). Moreover, cardiac function was similar in gsk3KI mice and gsk3WT
The differences in blood pressure and heart rate were in large part due to altered plasma 
catecholamine levels. Interestingly, the plasma concentrations of epinephrine, and 
norepinephrine were both significantly enhanced in gsk3
 mice under anaesthesia 
(Webb IG, et al., 2010).  
KI mice. Of note, epinephrine plasma 
levels measured during isoflurane anaesthesia were lower than during ether anaesthesia. This could 
be due to different lots of the ELISA test or the increased epinephrine release due to diethylether 
exposure (Laborie C et al, Neurosc Letters 2005). Thus, GSK3 apparently influences the synthesis 
of the catecholamines at an early step. In theory, the catecholamine concentrations could have 
been increased due to slowed degradation. However, the increased urinary excretion of the 
catecholamine metabolite vanilyl mandelic acid clearly demonstrates that excessive formation 
and not delayed degradation accounts for the enhanced catecholamine plasma levels in gsk3KI 
mice. Accordingly, increased catecholamine production presumably accounts for blood pressure 
increase and tachycardia of gsk3KI mice.  
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The gsk3KI
The present observations do not rule out further GSK3 sensitive mechanisms affecting blood 
pressure regulation. For instance, inhibition of GSK3 by lithium has been reported to upregulate 
endothelial nitric oxide synthase (eNOS) (Nakatani K, et al., 2004). 
 mice show hyperactive behaviour, which could further contribute or even 
account for the increased sympathetic activity. The role of GSK3 in the regulation of the 
sympathetic nerve system is further underscored by the contribution of GSK3 to the action of the 
drug cocaine.  
 
Accordingly, resistance of GSK3 to the inhibitory effect of PKB/SGK could, at least in theory, 
decrease eNOS activity, which may favor an increase in blood pressure in gsk3KI
 
 mice.  
The present observations strongly suggest, however, that the differences of blood pressure 
between gsk3KI and gsk3WT
 
 mice are in large part due to differences in adrenergic stimulation.  
The present paper does not define the origin of the catecholamines. However, increased 
catecholamine release has previously been shown to parallel manic behavior (Fitzgerald PJ, et 
al., 2009; Ising M, et al., 2006; Maas JW, et al., 1994 and Swann AC, et al., 1991), which has 
previously been observed in the gsk3KI mice (Ackermann TF, et al., 2010). 
 
The mice display increased curiosity, decreased anxiety, hyperactivity, and decreased immobility 
in the forced swimming test (Ackermann TF, et al., 2010). Along those lines, antimanic drugs, 
such as clozapine, olanzapine, lithium, and valproate, are considered to affect PKB-dependent 
regulation of GSK-3 (Aubry JM, et al., 2009; Gould TD, et al., 2005 and Klein PS, et al., 1996). 
 
Hyperactivity is similarly observed in transgenic mice overexpressing GSK-3 (Prickaerts J, et al., 
2006). GSK-3 overexpression upregulates PKB expression and downregulates expression of 
PPP2R3A, a regulatory subunit of the PKB-inactivating phosphatase PP2A, effects leading to 
eventual inhibition of GSK3 and thus mitigation of the phenotype (Prickaerts J, et al., 2006). In 
the gsk-3KI mice, this negative feedback is disrupted, and thus the phenotype is more pronounced 
than in GSK3 overexpressing mice. The role of GSK3 in the regulation of the sympathetic nerve 
system is further underscored by the contribution of GSK3 to the action of the drug cocaine 
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(Miller JS, et al., 2009). Collectively, those observations suggest that the enhanced 
catecholamine release is secondary to excessive central stimulation of the sympathetic nerve 
system. Along those lines, the differences in blood pressure between gsk3KI and gsk3WT
 
 mice 
were abrogated in the presence of ganglion blocker hexamethonium. 
The increased blood pressure of gsk3KI mice presumably contributes to proteinuria (Boini KM, et 
al., 2009) of those mice. Accordingly, the proteinuria of gsk3KI mice was abrogated by lowering 
of blood pressure with prazosin (Boini KM, et al., 2009). Renal injury following 18 days of 
mineralocorticoid excess was again more pronounced in gsk3KI than in gsk3WT mice (Boini KM, 
et al., 2009), a finding again likely to result from enhanced blood pressure in gsk3KI mice. 
Beyond its role in catecholamine release and blood pressure control, GSK3 plays a pivotal role in 
cardiac hypertrophy (Fiedler B, et al., 2004; Sugden PH, et al., 2008 and Trivedi CM, et al., 
2007). Specifically, gsk3KI
 
 mice are protected against cardiac hypertrophy following adrenergic 
stimulation (Webb IG, et al., 2010), and gene-targeted mice lacking GSK3α develop progressive 
cardiomyocyte and cardiac hypertrophy and contractile dysfunction (Zhou J, et al., 2010).  
In conclusion, we demonstrate that PKB/Akt/SGKdependent phosphorylation of GSK3 
participates in the control of catecholamine release and thus in blood pressure regulation. 
Disruption of the inhibitory effect of PKB/Akt/SGK on GSK3 leads to enhanced catecholamine 
release and increase of blood pressure. 
 
GSK3, Phosphaturia and Calciuria 
In an attempt to second aim, we confirmed the previous observation (Boini KM, et al., 2008) that 
creatinine clearance and urinary flow rate are higher in mice expressing protein kinase 
B(PKB)/serum and glucocorticoid-inducible kinase (SGK)-resistant glycogen synthase kinase 
GSK3 (gsk3KI). With further estimations of electrolytes we found that compared with wild-type 
mice (gsk3WT), gsk3KI
The homeostasis of inorganic phosphate is primarily determined by kidneys. The filtered 
Pi reabsorption is controlled by expression and activity of Na
 mice are both hypercalciuric ( high excretion of calcium in urine) and 
hyperphosphaturic (high excretion of phosphate in urine). 
+ -dependent phosphate transporters 
in the brush border membrane of the proximal tubule. These sodium-dependent Pi cotransporters 
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(Na/Pi-cotransporters) belongs to the SLC 20 (SLC20A2) and 34 (SLC34A1, SLC34A3) 
families. Therefore renal excretion of Pi is controlled by a number of hormones, including 
phosphatonins, and metabolic factors but only very little is known about intracellular signaling 
events mediating the control of these transporters (Biber J, et al., 2009, Murer H, et al., 2000 and 
2004 and Picard N, et al., 2010). Parathyroid hormone, dopamine, phosphatonins (FGF23, sFRP-
4, MEPE), glucocorticoids, atrial natriuretic peptide, phosphate loading, metabolic acidosis, 
carbonic anhydrase inhibitors and estrogen inhibits proximal tubular Pi reabsorption whereas 
growth hormone, insulin-like growth factors , 1,25(OH)2D3, and phosphate depletion increased 
Pi reabsorption. Our results showed that GSK3 plays an important role as evident from the 
stimulation of NaPi-IIa activity in Xenopus oocytes by GSK3 and the decreased phosphate fluxes 
in isolated BBMVs from gsk3KI
 As we know that phosphaturia may either primary (excess excretion of phosphate by 
kidney, as from primary renal dysfunction) or secondary (excess excretion of phosphate in urine 
due to hyperparathyroidism origin). The phosphaturia of gsk3
 mice. Reduced activity of SLC34 transporters (NaPi-IIa and 
NaPi-IIc) and other PFA-resistant phosphate transporters was detected. The expression of Pit2, 
resistant to PFA, was, however, not altered, suggesting that either only its activity is affected by 
GSK3 or other unknown PFA-resistant phosphate transporters contribute to the residual activity 
in the presence of PFA.  
KI
 Plasma PTH level is another major regulator of renal phosphate transport (Murer H, et 
al., 2000). PTH acts directly on proximal tubular cells and inhibits both apical and basolateral  
Na/pi cotransporters by mechanisms that involve the internalization of cell surface Npt2a protein 
(Kempson SA et al., 1995) and its subsequent lysosomal degradation (Pfister MK  et al., 1998). 
PTH binding to receptors on the basolateral membrane activates protein kinase A(PKA) and/or 
protein kinase C (PKC) signaling pathways, whereas PTH binding to apical receptors activates 
PKC (Traebert M, et al., 2000). The PKA and PKC signaling pathways converge on the 
extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) pathway to 
internalize Npt2a protein (Bacic D et al., 2003). Although the downstream targets for 
ERK/MAPK-mediated phosphorylation remain unknown, changes in the phosphorylation state 
of Npt2a are not associated with its PTH-induced internalization (Jankowski M et al., 2001). 
 mice cannot be explained by 
plasma phosphate concentration, which was actually significantly decreased.  
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Rather, regulation of Na/Pi cotransport by PTH may be achieved by the phosphorylation of 
proteins that associate with Npt2a. 
In brief PTH stimulates the internalization and subsequent degradation of NaPi-IIa (Murer H, et 
al., 2000 and Bacic D, et al., 2006). The hormone thus enhances renal phosphate excretion and 
decreases plasma phosphate concentration. A decreased plasma PTH concentration is thus 
expected to enhance renal phosphate reabsorption and to increase plasma phosphate 
concentration, which was the opposite of what we observed in gsk3ki
The release of PTH is mainly controlled by serum calcium concentration through 
negative feedback. Also partially decreased plasma phosphate concentration inhibits PTH release 
(Martin DR, et al., 2005). However, the decrease of the plasma phosphate level is very discrete 
and hardly accounts for the low plasma PTH levels.  
 mice.  
As we know that plasma PTH stimulates the renal 1α-hydroxylase (Portale AA, et al., 
2000), the rate-limiting enzyme of 1,25-(OH)2D3 formation (Portale AA, et al., 2000 and Kato 
S, 1999). Thus low plasma PTH levels are expected to decrease the plasma 1,25-(OH)2 D3 
concentration. As expected, the gsk3KI mice displayed decreased plasma 1,25-(OH)2 D3 
concentration. On the other hand, formation of 1,25-(OH)2D3 is stimulated in a PTH-
independent manner by cellular phosphate depletion (Perwad F, et al., 2005). The transcript 
levels of the 1α-hydroxylase tended to be enhanced in gsk3KI
However, PTH enhances the uptake of phosphate from the intestine into the blood 
(Brown AJ, et al., 2002). In the intestines, absorption of phosphate is mediated by an increase in 
activated vitamin D (1,25-(OH)2D3). Hence decreased 1,25-(OH)2D3 formation is expected to 
decrease intestinal phosphate absorption and that impaired intestinal phosphate uptake could 
contribute to the development of hypophosphatemia, which was found in gsk3
 mice. The possibility must be 
considered that GSK3 influences 1α-hydroxylase and 1,25-(OH)2D3 formation by further 
mechanisms in addition to its influence on phosphate balance and PTH plasma concentration.  
KI
Moreover, PTH enhances the absorption of calcium across the intestinal brush border 
membrane, passing through ion channels such as TRPV6 (
 mice.  
Barley NF et al., 2001). Calbindin is a 
vitamin D-dependent calcium-binding protein in intestinal epithelial cells which functions 
together with TRPV6 and calcium pumps (PMCA1) in the basal membrane to actively transport 
calcium into the blood. Thus gsk3ki mice having low plasma PTH and 1,25-(OH)2D3 expected to 
absorb less calcium to cause hypocalcemia. ,which could be compensated by bone resorption in 
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osteoclasts.  Since PTH and 1,25-(OH)2D3 stimulate renal tubular Ca2+ reabsorption via 
upregulation of the TRPV5 channel (Hoenderop JG, et al., 2005, Woudenberg-Vrenken TE, et 
al., 2009 and Friedman PA, 2000), the decreased plasma PTH and 1,25-(OH)2D3 concentration 
in gsk3KI mice could thus contribute to the calciuria of gsk3KI
Despite the decreased PTH plasma concentration, the bone mass was significantly 
decreased in gsk3
 mice by affecting translation, 
trafficking, and/or activity of TRPV5 channels. 
KI mice. Thus, the renal Ca2+ and phosphate loss of gsk3KI
In conclusion, Akt/PKB-dependent regulation of GSK3 participates in the control of renal 
tubular phosphate transport. Loss of Akt/PKB-dependent inhibition of GSK3αβ leads to renal 
phosphate wasting, which presumably contributes to or even accounts for the decrease of PTH 
release with resulting calciuria, decreased formation of 1,25-(OH)2 D3, and decreased 
mineralization of bone.  
 mice may impair 
mineralization of bone. Phosphate is known to inhibit the generation of new and to stimulate 
apoptosis of mature osteoclasts (Kanatani M, et al., 2003). Moreover, Akt/PKB-dependent 
regulation of GSK3 may more directly participate in the regulation of bone cells. Akt/PKB 
regulates the survival of both osteoblasts (Chaudhary LR, et al., 2001) and osteoclasts (Kwak 
HB, et al., 2008 and Lee SE, et al., 2002).  
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Fellowship of Academic Bodies 
Qualified GATE-98 with 97.11 percentile and obtained fellowship from AICTE. 
 
 
Conferences, Short Term Courses/Participated, Attended 
1. Completed training workshop on ‘Techniques of Animal Tissue Culture' 
conducted at Centre For Genetic Diagnosis, Deenanath Mangeshkar Hospital 
& Research Centre, Pune. 
   
2. Attended one day seminar on ‘Proteomics & Genomics sponsored by 
University of Pune on 1st
 
 Dec. 2007 at MMM’s College of Pharmacy, Pune. 
    
3. Attended ‘54th
 
 Indian Pharmaceutical Congress 2002’ at Bharati Vidyapeeth’s 
Poona College of Pharmacy, Pune. 
4. Participated one day seminar on ‘Rheololgy of Pharmaceutical and Cosmetic 
Products’ organized on 18th
 
 August 2003, at Bharati Vidyapeeth’s Poona 
College of Pharmacy, Pune. 
5. Attended ‘Refresher course Cum Workshop’ for Pharmacist sponsored by PCI 
conducted at Bharati Vidyapeeth’s Poona College of Pharmacy, Pune on 4th 
and 5th
 
 March 2000. 
 
Examiner/Paper setter/Moderator 
Appointed as Examiner, paper setter and moderator in Pune University, 
Shivaji University & SRTM University for undergraduate examination. 
 
 
  
Declaration 
 
The information given in these curriculum vitae is correct. 
Date: 26-07-2012 
 
 
Place: Tuebingen, Germany                           Balasaheb Siraskar 
 
 
